Helicobacter infection alters the phenotype and inflammatory response of mouse intestinal muscle macrophages by Hoffman (Brogan), Sara M.
  
HELICOBACTER INFECTION ALTERS THE PHENOTYPE AND INFLAMMATORY 
RESPONSE OF MOUSE INTESTINAL MUSCLE MACROPHAGES  
 
 
by 
 
 
 
SARA M. HOFFMAN (BROGAN) 
 
 
 
B.S., Kansas State University, 2005 
 
 
 
A THESIS 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 MASTER OF SCIENCE  
 
 
Division of Biology  
College of Arts And Sciences  
 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2008 
 
Approved by: 
 
Major Professor 
Dr. Sherry D. Fleming 
  
Abstract 
Helicobacter is a common intestinal pathogen of most laboratory mice from both 
commercial and academic sources worldwide. Not previously thought to have an effect, 
recent evidence indicates Helicobacter infection alters cytokine, chemokine, and gene 
expression in the stomach, intestine, and colon. Though the in vivo cell types responsible 
for these changes are currently unknown, in vitro results suggest macrophages are the 
likely source. In addition to detection and elimination of pathogens, intestinal 
macrophages play a role in maintaining homeostasis. By altering gene expression and 
cytokine production in the microenvironment, we hypothesized that Helicobacter 
infection altered the phenotype and inflammatory response of submucosal intestinal 
macrophages.  
 
To test this hypothesis, we examined macrophages within whole mounts of 
intestinal muscle as well as isolated macrophages from Helicobacter-infected or 
uninfected mouse intestine. Macrophages from the intestinal muscle of Helicobacter-
infected mice showed increased expression of F4/80 and CD11b, altered gene expression, 
and increased phagocytosis when compared to macrophages from uninfected mice. 
Infection also altered the macrophage response to stimuli. Macrophages from infected 
mice produced significantly lower concentrations of cytokines, chemokines, and PGE2 in 
response to stimulation with either IFN and LPS or IL-4 and IC. These data support our 
hypothesis demonstrating that the intestinal muscle macrophage phenotype, function, and 
response to stimulation are altered by Helicobacter infection both in vivo and in vitro. 
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CHAPTER 1 - Introduction 
I. The Intestine 
A. Mucosal Immunity 
Mucosal and epithelial surfaces come into contact with environmental 
microorganisms immediately after birth. Due to constant direct exposure to microbes, 
these surfaces developed many protective mechanisms to resist invasion (reviewed in 
(1)). Multiple layers of epithelial cells protect the skin’s surface (2), but only a single 
layer of epithelium covers the surfaces of the gastrointestinal (3), respiratory (4), and 
urogenital tracts (5). Therefore, these systems require more comprehensive protection (1). 
This protection comes from multiple mechanical and chemical barriers which break down 
and remove foreign substances (1). In addition, a very effective innate immune system 
and a highly specific adaptive immune system protect mucosal sites of higher organisms 
(1, 6, 7). 
 
The mucosal immune system provides protection against pathogenic 
microorganisms. Protective mechanisms include the innate immune system and barrier 
function. A strong innate immune response neutralizes pathogens and prevents infections 
once the barrier is broken (1). Barrier function consists of preventing penetration by 
immunogenic components such as bacteria from mucosal surfaces (reviewed in (1, 8)). 
Other important roles of mucosal immunity include mucosal tolerance, which is the 
induction of unresponsiveness to some antigens (9), immunoregulatory functions (10), 
and maintaining mucosal homeostasis (1).  
 
Mucosal immunity is dominated by innate immune processes that protect the 
organism within the first minutes and hours of exposure to foreign substances or infection 
(reviewed in (1, 6)). Innate immunity recognizes and distinguishes between the antigens 
of pathogenic microbes and the harmless components of microbial commensals (1, 6). 
Once recognized, a host defense response clears the invading pathogen (1, 6). Along with 
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many other molecules, this involves pattern recognition receptors (PRRs) which 
recognize and respond to conserved sequences present on pathogenic and commensal 
microorganisms (1, 11). After binding PRRs, microbial molecules, such as 
lipopolysaccharide (LPS) and peptidoglycan, trigger cytokine and chemokine production 
(1, 11). Phagocytosis by macrophages and neutrophils also removes pathogens ((12, 13) 
reviewed in (14)). 
 
The primary mechanical barrier of most mucosal surfaces consists of single layer 
of several types of interconnected, polarized, epithelial cells (reviewed in (1)). Tight 
junctions reinforce the intestinal epithelial layer. These junctions connect adjacent 
epithelial cells and aid in forming an interconnected network (1). Tight junctions also 
maintain epithelial cell polarity and act as ports of entry that open and close in response 
to signals from the lumen, lamina propria or epithelium (1, 15). Many types of epithelial 
cells participate in mucosal barrier function, including enterocytes and colonocytes (1, 6). 
Barrier function also involves specialized epithelial cells such as goblet and Paneth cells 
(1, 6). Goblet cells produce mucus for protection and trefoil peptides required for 
epithelial growth and repair, while Paneth cells secrete antimicrobial peptides such as 
defensins (1, 6). 
 
Intestinal epithelial cells play an essential part in the natural defense mechanism 
of mucosal surfaces. They are involved in various immune processes in addition to their 
absorptive, digestive and secretory functions (reviewed in (1)). The intestinal epithelium 
produces an array of cytokines, chemokines, and antimicrobial peptides as well as 
providing a physical barrier (1). Epithelial cell lines, constitutively or upon stimulation, 
produce a number of cytokines, chemokines and inflammatory mediators including 
interleukin 6 (IL-6), IL-8, and monocyte chemoattractant protein 1 (MCP-1) (1, 16). 
These pro-inflammatory cytokines, also produced by macrophages and T cells, influence 
epithelial cell physiology and function (1). Stimulation of epithelial cells with interferon 
γ (IFN-γ), IL-1, or tumor necrosis factor α (TNF-α) increases expression of PRRs and 
other surface molecules as well as production of cytokines and chemokines (1, 17, 18). 
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Finally, epithelial cells present antigens which may induce anergy rather than activation 
(19-21). 
 
B. Immune cells of the Intestine 
The gut associated lymphatic tissue is the largest lymphatic organ of the body 
(22). Mucosa-associated lymphatic tissue consists of lymphatic follicles, Peyer’s patches, 
the appendix, and freely dispersed, lamina propria lymphocytes (1, 22). These cooperate 
with other components of the innate immune system to initiate adaptive immune 
responses (1, 22). Some organized lymphatic tissues such as follicles are covered with an 
epithelial layer containing specialized epithelial cells called M cells (1, 23). Pinocytic M 
cells absorb and transport antigens from the intestinal lumen to Peyer’s patches resulting 
in T cell activation and induction of mucosal immunity (1, 23).  
 
Lamina propria leukocytes are a critical effector component of mucosal immunity 
(1). Intraepithelial lymphocytes, present in the epithelium and on the basolateral side of 
enterocytes, are predominately CD8+ and γδ T cells which may have a limited range of 
specificities (1, 24-26). These T cells identify proteins not normally present in the 
epithelium and kill damaged or altered epithelial cells (1). Intraepithelial and lamina 
propria dendritic cells sample the lumen by forming transepithelial dendrites (27, 28). 
These cells then stimulate an immune response to detected pathogens by carrying them to 
the Peyer’s patches and lymph nodes (29) or stimulate immune tolerance by transporting 
apoptotic epithelial cells to lymph nodes (30). Diffuse lymphocytes of the lamina propria 
are the most varied and the most active mucosal effector cells (1). They include CD4+ T 
cells (31), B cells producing polymeric IgA (32), eosinophils (33), neutrophils (33), mast 
cells (34) and macrophages (35). Large numbers of macrophages are also present in the 
muscle layers surrounding the intestine, but their function is not well defined (36, 37). 
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II. Macrophages 
A. General Information 
Macrophages are white blood cells that display varied phenotypes and functions 
depending upon tissue location in the host. Many innate and adaptive immune processes 
involve macrophages. One important function is clearance of pathogens and apoptotic 
bodies via phagocytosis. Macrophages recognize and ingest fungi, bacteria, viruses, 
cellular debris, and immune complexes (reviewed in (38-40)). Inside vesicles called 
phagosomes, macrophages kill and/or break these components down by nutrient 
deprivation, antimicrobial peptides, or reactive oxygen and nitrogen species (reviewed in 
(41)).  
 
Once a pathogen has been phagocytosed and degraded, macrophages present 
foreign proteins to T cells and B cells in major histocompatibility complex molecules on 
the cell surface (42). Though macrophages present antigen, dendritic cells are more 
effective (43, 44). This stimulatory signal activates T cells and B cells to produce 
cytokines and/or antibodies to help combat the pathogenic challenge. Additionally, 
macrophages produce a wide variety of cytokines, chemokines and lipid mediators in 
response to a range of stimuli including lipopolysaccharide, immune complexes and other 
cytokines (45). 
 
Wound healing and tissue repair after injury or inflammation is another 
characteristic of macrophages (46). To facilitate restoration of blood flow to healing 
tissue, macrophages release angiogenic molecules such as vascular endothelial growth 
factor and fibroblast growth factor into the extracellular matrix (47). These factors, which 
aid in the rebuilding of blood vessels, are produced in response to hypoxia and low 
extracellular pH due to anaerobic cell metabolism (48). Though typically associated with 
tissue damage, nitric oxide (NO) produced by macrophages can promote tissue repair in 
the skin (49, 50). Alternatively activated macrophages also support tissue repair by 
production of fibronectin (51), and induction of arginase in response to Th2 cytokines 
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(52, 53). This leads to urea and ornithine synthesis, as well as production of polyamines 
that promote cell proliferation and prolines required for collagen synthesis (54). 
 
Macrophages demonstrate a broad array of functions and phenotypes. It remains 
unclear whether macrophage characteristics are predetermined (45) or constantly 
changing (55). However, macrophages readily change their phenotype and function 
depending on the stimuli in the microenvironment both in vivo and in vitro (55-57). 
Therefore, it is likely that macrophages exist in varying activation states capable of 
reacting to changes in the microenvironment in response to injury or inflammation. 
 
B. Macrophage Stimulation 
The functional plasticity of macrophages allows them to respond to various 
stimuli in a multitude of ways. These stimuli include growth factors, cytokines, and 
chemokines, as well as bacteria, viruses, parasites, complement proteins, antibodies, 
immune complexes, damaged cells and a wide range of foreign peptides. Exposure to 
growth factors induces monocytes and bone marrow precursors to differentiate into 
macrophages (58-61). Contact with cytokines and pathogenic components either in vivo 
or in vitro stimulates macrophages to mature, change surface marker expression and in 
some cases change phenotypes (55-57, 62-65). 
 
In vitro, macrophages differentiate from monocytes using growth factors such as 
monocyte-colony stimulating factor (M-CSF), also known as colony stimulating factor-1 
(CSF-1) (60). M-CSF, produced by macrophages and activated T cells (66, 67), promotes 
proliferation and differentiation of monocytes and macrophages (68). Produced by 
macrophages, T cells, fibroblasts and endothelial cells, granulocyte/macrophage colony 
stimulating factor (GM-CSF) also stimulates the growth and differentiation of 
macrophages (reviewed in (61)). GM-CSF and M-CSF promote differentiation of bone 
marrow cells into two different phenotypes of macrophages, pro-inflammatory, type 1 
(M1) macrophages and anti-inflammatory, type 2 (M2) macrophages, respectively (58, 
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69). These two macrophage phenotypes have different morphology, cytokine expression, 
and gene expression as well as slightly different surface marker expression (58, 69). 
 
Macrophages mature and further differentiate in response to a variety of stimuli. 
Some stimuli induce a classically activated, M1 macrophage phenotype while others 
induce an alternatively activated, M2 macrophage phenotype. IFN-γ, secreted by Th1 
cells in response to infection, contributes to leukocyte recruitment (70). It also induces an 
M1 macrophage phenotype and stimulates macrophages to kill phagocytosed bacteria 
(71). LPS, a gram negative bacterial surface protein, activates macrophages through Toll-
like receptor 4 (TLR4) which stimulates pro-inflammatory cytokine production by M1 
macrophages (72). In contrast, IL-4 is an anti-inflammatory cytokine produced by Th2 
(73) and natural killer T cells (74). IL-4 induces macrophages to develop into an 
alternatively activated, M2 macrophage phenotype (69, 75). Immune complexes (IC), 
antigen-antibody aggregates, stimulate M2 macrophages to produce anti-inflammatory 
cytokines, but do not stimulate M1 macrophages (75).  
 
In addition to being stimulatory, LPS activation induces production of a number 
of inhibitors and negative regulators of LPS signaling, thereby reducing downstream pro-
inflammatory cytokine production (76, 77). ST2/T1, a member of the IL-1 receptor (IL-
1R) family, is an inhibitor of LPS signaling. Mast cells (78), fibroblasts, macrophages, 
and Th2 T cells (77, 79) express ST2 in a membrane bound form. In response to LPS, 
ST2 down-regulates TLR4 expression and inhibits signaling through TLR4 and IL-1R 
thereby inducing tolerance (77, 80). Mice lacking ST2 do not develop tolerance to LPS 
(80). ST2 also exists in a soluble form (sST2) which has anti-inflammatory effects 
directly on macrophages (77). LPS induces both membrane-bound and soluble ST2 in 
alveolar macrophages (76). However, the lack of ST2 results in decreased numbers of 
F4/80+ macrophages and increased inflammation in the lung (81). This suggests ST2 also 
modulates lung inflammation (76, 81). Although sST2 does not affect IL-10 or NO 
production, treatment of bone marrow-derived macrophages with sST2 inhibits IL-6, IL-
12 and TNF-α production after LPS stimulation (77). Soluble ST2 also decreases 
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inflammation due to collagen-induced arthritis (82) and inhibits inflammation after 
intestinal ischemia reperfusion by increasing IL-10 (83).  
 
Single immunoglobulin IL-1R-related molecule, SIGIRR (also known as Toll IL-
1R 8) is a member of the TLR-IL-1R superfamily that negatively regulates immune 
responses (84). Macrophages and dendritic cells express SIGIRR at low levels, but 
epithelial cells express the molecule at high levels (85, 86). It can block both IL-1R and 
TLR4 signaling (85, 87-89) though these inhibitions occur through different mechanisms 
(90). Expression of SIGIRR on colonic epithelial cells has an important role in gut 
homeostasis and intestinal inflammation in response to commensal microorganisms (91). 
Lack of SIGIRR results in enhanced inflammation after administration of IL-1 and 
increased lethal susceptibility to LPS (84). In the absence of SIGIRR, PGE2 and pro-
inflammatory cytokine and chemokine concentrations increased in the intestine (92). This 
correlated with an increased susceptibility to intestinal cancer (92).  
 
Interleukin-1 receptor-associated kinase of monomyeloic origin (IRAK-M) (93, 
94), a molecule expressed by monocytes and macrophages (95), negatively regulates 
TLR signaling and plays a role in innate immune homeostasis (96). The up-regulation of 
IRAK-M by macrophages leads to both LPS and peptidoglycan tolerance (95, 97, 98) as 
well as tolerance to tumor cells (99). S-nitrosoglutathione, a NO donor, induces IRAK-M 
over-expression and leads to LPS tolerance (100). NO stimulates TNF-α expression by 
monocytes which induces IRAK-M in an autocrine manner (100). Anti-TNF-α antibodies 
inhibit IRAK-M expression suggesting that TNF modulates IRAK-M associated LPS 
tolerance (100). In a murine model of sepsis, IRAK-M mediates immunosupression and 
tolerance to secondary infections leading to decreased macrophage function in the lungs 
without altering TLR2 or TLR4 expression (101). In the absence of IRAK-M, 
macrophages increase inflammatory cytokine production in response to bacteria (96, 
101). IRAK-M deficient mice also show significantly decreased tolerance to LPS and 
increased inflammation during bacterial infection (96) indicating an important role for 
IRAK-M in the response to LPS.  
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C. Types of Macrophages 
Human 
In vitro studies categorize activated macrophages into two types: classically or 
alternatively activated. Classical activation of macrophages by IFN-γ and LPS results in 
an M1 macrophage phenotype (70, 72). These classically activated, M1 macrophages 
secrete pro-inflammatory cytokines and support Th1 responses (69). Human blood-
derived monocytes isolated by CD14+ bead separation and cultured with GM-CSF 
display an M1 macrophage phenotype (69). They secrete IL-12, IL-1β, IL-6, and TNF-α 
upon stimulation with LPS in the presence or absence of IFN-γ (69). Alternative 
activation of macrophages by IL-10 or the combination of IL-4 and IC results in an M2 
phenotype. Alternatively activated, M2 macrophages secrete anti-inflammatory 
cytokines, support Th2 responses, and play a role in regulating cellular immunity and 
homeostasis (69, 102). When cultured in M-CSF, CD14+ human blood-derived 
monocytes display an M2 macrophage phenotype, secreting IL-10 upon stimulation with 
LPS (69).  
 
Though having different morphologies, with M1 macrophages appearing rounded 
and M2 macrophages having long dendrite-like protrusions, M1 and M2 macrophages 
derived from human monocytes express similar levels of most surface markers (69). The 
only difference detected was in expression of CD163, a scavenger receptor, which was 
ten-fold higher on M2 macrophages (69). Both M1 and M2 macrophage phenotypes 
secrete IL-8, MCP-1, interferon inducible protein-10 (IP-10), and macrophage 
inflammatory protein 1 (MIP-1) in response to LPS stimulation (69). 
 
Mouse 
Unlike human monocytes, M-CSF induces both M1 and M2 macrophage 
phenotypes from mouse bone marrow (75) (Table 1). A classically activated, M1 
macrophage phenotype results from LPS and IFN-γ stimulation of M-CSF cultured 
mouse bone marrow macrophages (75). These macrophages produce high levels of pro-
inflammatory IL-12, IL-1 and TNF-α (75). In addition, M1 macrophages metabolize 
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arginine to NO as well as expressing inducible nitric oxide synthase (iNOS), one of the 
genes reponsible for NO synthesis (75). 
 
Using mouse bone marrow, recent in vitro studies have revealed two distinct 
types of alternatively activated M2 macrophages (Table 1). The first M2 macrophage 
phenotype develops in response to M-CSF and IL-4. Unlike M1 macrophages, these cells 
do not express iNOS or produce NO (75). However they metabolize arginine to urea, 
which promotes tissue repair by inducing collagen production, via Arginase-1 (Arg-1) 
(54, 75) and produce low levels of IL-10, which down-regulates Th1 responses, upon 
stimulation (103). The presence of Arg-1, Fizz-1 (found in inflammatory zone-1), and low 
expression of Sk-1 identify this type of M2 macrophage (75, 104-106). Fizz-1 produces a 
cysteine-rich secreted protein that may be involved in tissue repair (105). A second M2 
macrophage phenotype, developing in response to M-CSF and IC, expresses iNOS and 
produces NO similar to M1 macrophages (75). Unlike the other M2 macrophage 
phenotype, these macrophages produce large amounts of IL-10 and express high levels of 
Sphingosine kinase-1 (Sk-1) (75). Other M2 macrophages, but not M1 macrophages, also 
express Ym-1, a heparin-binding lectin that may be involved in tissue repair (104, 107).  
 
The identification of the second M2 macrophage phenotype that has 
characteristics of both M1 and M2 macrophages confounds the current model of 
macrophage classification. Although this study classified this intermediate phenotype as 
an M2, it suggests that the model is not sufficient to describe the observed macrophages 
phenotypes induced in vitro. In addition, this model likely does not apply to all 
macrophages found in vivo since there is high variability in the phenotypes and functions 
of tissue macrophages. 
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Table 1. Summary of Mouse Macrophage Phenotypes 
 M1 MΦ-Classical                 M2 MΦ-Alternative 
 Ca MΦ (75) MII MΦ (75) AA MΦ (75) 
Cultured in M-CSF M-CSF M-CSF 
Stimulation LPS+IFN LPS+IFN+IC IL-4 
Cytokines IL-12 IL-10 IL-10 
NO High High Very low 
Urea/Arginase Low Low High 
Gene expression 
 
iNOS, IL-12p40 
 
iNOS, Sk-1, IL-10 
 
Arg-1, Fizz-1, Sk-1lo 
 
 
 
In addition to gene expression and cytokine production, surface markers identify 
macrophages. CD115, a growth factor receptor also known as CSF -1 receptor or c-fms 
(108), and major histocompatibility complex II (MHC-II) (109, 110) are expressed on 
most macrophages. Most macrophages and neutrophils also display surface CD14 and 
TLR4, parts of the LPS co-receptor (111), and CD11b (Mac-1) (112) . However, CD83+ 
dendritic cells also express CD11b and TLR4 (113). CD36, a scavenger receptor, 
identifies most macrophages but endothelial cells may express CD36 and TLR4 (114). 
Mature macrophages specifically express F4/80 (115). Depending on tissue location and 
activation state, levels of these markers vary on the cell surface.  
 
Culture with M-CSF followed by cytokine treatment has been traditionally 
thought to terminally differentiate macrophages. However, macrophages may reversibly 
change phenotypes and functions depending on stimuli present (55, 56). In vitro, 
cytokines induce an array of phenotypes in bone marrow-derived macrophages, 
peritoneal macrophages, and macrophages from tumor bearing mice (55, 56). Changing 
the cytokines present in the culture reverses or alters these phenotypes (55, 69, 75). For 
example, treatment of bone marrow macrophages with IFN-γ induced production of 
TNF-α and IL-12 upon stimulation with LPS (55). However, IFN-γ priming followed by 
IL-10 treatment resulted in decreased TNF-α and IL-12 along with increased IL-10 after 
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LPS stimulation (55). This indicates that the composition of the microenvironment prior 
to bacterial contact yields different immunologic responses. Additionally, mouse bone 
marrow macrophages activated with IFN-γ and LPS change their phenotype from M1 to 
M2 in response to FcγR ligation or IC stimulation after removal of IFN-γ and LPS (102). 
Therefore peritoneal and bone marrow-derived macrophages likely represent a malleable 
set of immunologically active cells rather than fixed subpopulations. However, it is 
unclear if further differentiated resident tissue macrophages respond to stimuli in a 
similar manner. 
 
D. Intestinal Macrophages 
The intestine contains the largest population of macrophages in the body (116). 
Recent studies investigated the phenotype and function of these macrophages in humans, 
rats and mice, with those from humans being better characterized (36, 37, 117-124). 
However, there is not a consensus on the phenotype or function of intestinal 
macrophages. The disparities in observed phenotypes may be due in part to isolation of 
macrophages from different intestinal tissues using a variety of separation and digestion 
methods. Nevertheless, the observed intestinal macrophage phenotypes do not coincide 
with a classical M1 macrophage phenotype.  
 
Human 
Analysis of several studies suggests that the isolation method may alter the 
expression of macrophage cell surface markers (117-120). Initial studies isolated human 
macrophages by treatment with EDTA to remove the epithelium (de-epithelialized) 
followed by enzymatic digestion of the remainder of the tissue. Then gradient 
sedimentation and counterflow centrifugal elutriation separated the macrophages based 
on size and density (117-119). These macrophages retained avid phagocytic and 
bactericidal activity (117, 118). Macrophages isolated from human intestinal tissue 
expressed MHC-II, CD13 (aminopeptidase N), CD36, TLR4, and TLR2 (118, 119), 
though some of these markers were expressed at very low levels. Unlike most 
macrophages, the enzyme digested macrophages did not express CD14, CD11b (CR3), 
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CD11c (CR4), or α integrin CD11a (LFA-1) as determined by flow cytometry (117-119). 
These macrophages had decreased responses to LPS. In response to LPS, IFN-γ, or heat-
killed Staphylococcus aureus, they produce low levels of IL-8 and do not produce IL-1, 
IL-6, IL-12, TNF-α, or IL-10 (117). This decreased effect may contribute to the low level 
of inflammation in normal intestine despite the presence of bacteria and other pro-
inflammatory molecules (117). 
 
In a more recent study, human intestinal macrophages were isolated by enzyme 
digestion and sedimentation in the same manner as above or allowed to migrate out of de-
epithelialized whole intestine (120). Similar to digested macrophages, human intestinal 
macrophages allowed to migrate out of de-epithelialized whole intestine expressed TLR2 
and TLR4 (120). However, unlike the digested macrophages, migrated macrophages 
expressed CD14 and produced TNF-α in response to LPS and E. coli particles (120). It is 
unclear whether the observed differences in macrophage phenotype result from contact 
with stromal cells during migration or from removal by enzyme digestion.  
 
Interestingly, macrophages can also be found in the muscle layers surrounding the 
small and large intestine (121). These macrophages are responsible for production of pro-
inflammatory cytokines that contribute to postoperative ileus after surgery or 
transplantation in both humans (125) and rodents (126). Therefore, despite expressing 
abnormally low levels of most of the typical macrophage markers, intestinal macrophages 
appear to have normal functions. 
 
Rat 
Similar to those seen in humans, macrophages in rats form a regularly distributed 
network in the muscle layers surrounding the intestine. In whole muscle mounts 
examined by immunohistochemistry (IHC), these cells express ED2 (similar to F4/80 in 
mice), MHC II, CD14, and low levels of CD11a (36). ED2+ macrophages in the tissue 
produce NO and prostaglandin E2 (PGE2) in response to LPS treatment corresponding to 
increased iNOS and cyclooxygenase-2 (COX-2) expression, respectively (65). When 
isolated by collagenase/dispase digestion from rat intestinal muscle, these macrophages 
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do not proliferate in culture but do change morphology over time (36). Early after 
adhesion, the macrophages appear round then develop a stellate configuration with 
elongated processes after 2-3 days in culture (36). Initially 90% of the macrophages 
express ED2 and phagocytose Fitc dextran (36). If not passaged, these macrophages 
retain the normal resident macrophage phenotype for several weeks in culture (36). 
However, after three passages, ED2 staining and phagocytic activity are lost (36).  
 
When compared to those from the peritoneum, intestinal macrophages isolated 
from the colon of rats by collagenase digestion have lower CD14 mRNA and surface 
expression than peritoneal macrophages (123). Colonic macrophages are phagocytic but, 
unlike those in intestinal whole muscle mounts, do not produce NO or TNF-α in response 
to LPS (123). Similar to those in humans, macrophages in the intestinal muscle form a 
network of phagocytic cells that express ED2. These cells are also observed in mice.  
 
Mouse 
F4/80+ resident macrophages form a regularly distributed network in the muscle 
layers surrounding the intestines of normal and germ-free mice (122, 127, 128). Similar 
to human and rat, macrophages isolated from whole mouse intestine by 
collagenase/dispase enzyme digestion express F4/80 and MHC II (124). Macrophages 
isolated from only the intestinal muscle also express F4/80 and MHC II, as determined by 
IHC, and take up Fitc dextran (37). 
 
Resident muscle macrophages mediate inflammation by changing the phenotype 
of newly recruited monocytes. For example, in vivo, injured skeletal muscle tissue 
recruits pro-inflammatory F4/80lo monocytes that switch to anti-inflammatory F4/80hi 
macrophages (129). In vitro, phagocytosis of necrotic muscle cell debris also induces pro-
inflammatory macrophages to change to an anti-inflammatory phenotype (129). It is 
likely that intestinal muscle macrophages respond in a similar manner. This ability has 
important implications for both tissue damage and repair mechanisms mediated by 
macrophages. In addition, the absence or depletion of macrophages in the intestine 
decreases inflammation after surgery (126). Significantly lower production of IL-1β, IL-
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6, and MIP-1α mRNA suggest that resident muscularis macrophages mediate intestinal 
inflammation (126). Together these data indicate resident intestinal muscle macrophages 
play an important role in mediating inflammation in the intestine in response to injury. 
This also suggests that these macrophages may be involved in the response to intestinal 
infections. 
 
E. Cytokines, Chemokines, and Arachidonic Acid Metabolites by Macrophages 
Macrophages are one of the primary cytokine secreting immune cells. In response 
to stimulation with a wide range of ligands, macrophages produce an array of pro-
inflammatory, anti-inflammatory, and homeostatic cytokines (45). Macrophages also 
secrete other inflammatory mediators such as prostaglandins, leukotrienes, nitric oxide, 
and urea to regulate the immune response (45). 
 
Cytokines and Chemokines 
IL-1α and IL-1β, members of the IL-1 superfamily, are pro-inflammatory 
cytokines produced by macrophages and dendritic cells in response to LPS binding TLR4 
(72, 130). During the inflammatory response, these cytokines increase the expression of 
adhesion factors on endothelial cells to enable transmigration of leukocytes to sites of 
infection (131). IL-1 also causes fever by re-setting the hypothalamus (132, 133).  
 
IL-6 is a pro-inflammatory cytokine secreted by macrophages and T cells 
dispersed in the lamina propria of the intestine as well as macrophages found in other 
tissues. These cells secrete IL-6 in response to infection, tissue damage, transplant, or 
graft (134, 135). IL-6, similar to IL-1, mediates fever and the acute phase response (133). 
In addition to being pro-inflammatory, IL-6 has anti-inflammatory effects. By inducing 
the expression of IL-4, IL-6 promotes Th2 differentiation and impaired Th1 
differentiation (reviewed in (136)). In response to muscle contraction the muscle itself 
produces IL-6 (137). This may inhibit the effects of pro-inflammatory cytokines during 
exercise (137) and play a role in the inflammatory response in the vascular system (138). 
In the muscle and fatty tissue, IL-6 produced by both muscle cells and macrophages 
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stimulates energy mobilization which leads to increased body temperature. This can 
occur in response to LPS, TNF-α and IL-1β (139). 
 
IL-10 is an anti-inflammatory cytokine produced by B cells (140), T cells (141), 
mast cells (142), and macrophages (143). It inhibits production of pro-inflammatory 
cytokines such as IFN-γ, IL-12, and TNF-α by macrophage and other cell types (144, 
145). IL-10 also suppresses antigen presentation by macrophages and dendritic cells 
(146). Correlating with decreased pro-inflammatory responses, IL-10 stimulates Th2 cells 
to up-regulate anti-inflammatory cytokines in response to infection or injury (147). 
 
IL-12 is a pro-inflammatory cytokine produced by macrophages, dendritic cells 
and B cells in response to bacterial challenge (148). IL-12 differentiates naive T cells into 
pro-inflammatory Th1 cells (149) and reduces IL-4 mediated suppression of the 
inflammatory response (150). In addition, macrophages produce TNF-α in response to 
IL-12. By controlling the levels of other cytokines, IL-12 also mediates anti-angiogenic 
properties (151). IL-12 controls IFN-γ production by T cells (152), which in turn 
increases the production of IP-10, ultimately blocking the formation of new blood vessels 
(151).  
 
IP-10 (CXCL10) is a chemokine induced by IFN-γ in a variety of cell types 
including neutrophils (153), macrophages, endothelial cells, keratinocytes, fibroblasts 
(154), and activated T cells (155). LPS induced IFN-γ mediates IP-10 production (156). 
As a chemoattractant for monocytes and T cells (157), IP-10 promotes adhesion to 
endothelial cells. Also an angiostatic factor, IP-10 inhibits tumor growth and metastasis 
by preventing angiogenesis (151, 158).  
 
Keratinocyte-derived chemokine (KC), the mouse ortholog of IL-8 or CXCL8, is 
a chemokine produced by macrophages, endothelial cells and epithelial cells that is often 
associated with inflammation (159). Macrophages release large amounts of KC after 
phagocytosis of pathogens or foreign particles (160) and in response to inflammation 
(161). KC then induces neutrophil infiltration and activation at the site of inflammation 
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(162). Also playing a role in induction of systemic inflammation and tissue damage after 
injury (163), MCP-1 regulates KC (164). 
 
MCP-1, also known as CCL2, is produced by macrophages in response to LPS 
and IFN-γ during infection (165). Though it is not known as a potent neutrophil 
chemoattractant, MCP-1 mediates polymorphonuclear cell (PMN) infiltration by 
regulating levels of KC after injury or inflammation (164). MCP-1 also plays a role in 
many macrophage-associated processes as demonstrated by MCP-1−/− mice (reviewed in 
(166)). In response to myocardial ischemia, these mice exhibit reduced macrophage 
infiltration and activation, suppressed cytokine synthesis, and delayed phagocytic 
removal of dead cardiomyocytes. In addition, after myocardial infarction, myofibroblasts 
do not accumulate during tissue repair resulting in decreased ventricular remodeling 
(166).  
 
Macrophage inflammatory proteins MIP-1α and MIP-1β, CCL3 and CCL4 
respectively, are chemokines produced by macrophages, neutrophils, and dendritic cells 
after LPS stimulation (167-171). Both MIP-1α and MIP-1β lead to neutrophilic 
infiltration during inflammation followed by activation of these cells (172, 173). MIP-1α 
recruits macrophages to sites of inflammation. Subsequently, MIP-1α activates these cells 
to produce pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α (174). MIP-1α may 
also play a role in the progression of inflammation from neutrophil-dominated to 
macrophage-dominated over time (169).  
 
TNF-α is a cytokine produced primarily by macrophages in response to LPS (175, 
176), but is also made by mast cells (177, 178) and endothelial cells (18). Involved in 
both local and systemic inflammation, TNF-α stimulates the acute phase response (179), 
regulates inflammation and tumorigenesis (reviewed in (180)), and induces fever (181). 
TNF-α also controls apoptosis, proliferation, and differentiation of immune cells (182, 
183). A potent neutrophil chemoattractant (reviewed in (184)), TNF-α aids in adhesion of 
neutrophils to endothelial cells and transmigration to sites of infection (131, 185). In 
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addition, TNF-α stimulates macrophages to become more phagocytic (186) and induces 
the production of inflammatory molecules such as IL-1 (187).  
 
Arachidonic Acid and Arginine Metabolites 
Arachidonic acid, a precursor for several biologically active compounds, is 
derived from membrane phospholipids by phospholipases (reviewed in (188)). Five-
lipoxygenase breaks down arachidonic acid into leukotriene B4 (LTB4), a leukotriene 
involved in the inflammatory response (reviewed in (189)). LTB4 is a potent neutrophil 
chemoattractant which induces the formation of reactive oxygen species and the release 
of lysosomal enzymes by these cells (190, 191). Produced by monocytes during 
inflammation (192), LTB4 induces activation and adhesion of leukocytes to the 
endothelium aiding transmigration to sites of infection or damage (190, 193).  
 
Prostaglandin E2 is also a derivitive of arachidonic acid (reviewed in (188)). 
PGG2 and PGH2 are synthesized from arachidonic acid by COX and converted to PGE2 
by PGE2 isomerase ((194), reviewed in (188)). COX-1 constitutively produces PGE2, 
while in response to stimulation COX-2 induces additional PGE2. PGE2 plays an 
important role in various biological events such as apoptosis, tumorigenesis, and 
inflammation (reviewed in (195)). Produced in large concentrations early in 
inflammation, PGE2 promotes vasodilatation and increases vascular permeability 
indirectly by enhancing the release of histamine and other mediators from tissue 
leukocytes (reviewed in (196)). As inflammation progresses, macrophages alter PGE2 
synthesis (196). In chronic conditions, PGE2 inhibits leukocyte activation and cytokine 
secretion which aids in regulating and shutting down the inflammatory response (196). 
The pro- or anti-inflammatory properties of PGE2 are concentration dependent. Low 
constitutive levels of PGE2 produced primarily by COX-1 are responsible for homeostasis 
and physiological functions, while the induction of COX-2 results in high levels of PGE2 
that stimulates inflammation (197).  
 
Different types of macrophages metabolize arginine, the amino acid precursor for 
nitric oxide and urea, differently. In response to LPS or IFN-γ, M1 macrophages and 
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neutrophils use iNOS to metabolize L-arginine to NO (52). NO is toxic to bacteria and 
aids in clearance of pathogens when released into the microenviromnent (198). Besides 
being antimicrobial and cytotoxic, NO also plays an important role in tissue repair in the 
skin, with inhibition of NO production leading to decreased epithelial repair (49, 50).  
 
In response to IL-4, IL-10, and PGE2, M2 macrophages express Arg-1 which 
metabolizes L-arginine to urea and ornithine (52, 53). Urea production can identify 
alternatively activated macrophages (75, 199). Ornithine production by Arg-1 is the first 
step in the polyamine and proline synthesis that is neccesary for wound healing, tissue 
repair, smooth muscle growth, and collagen synthesis (reviewed in (200)). Arg-1 also 
inhibits production of NO (200).  
 
In conclusion, both M1 and M2 macrophages are important regulators of 
inflammation. They produce an array of pro- and anti- inflammatory cytokines, 
chemokines and other inflammatory mediators in response to stimuli (45). Since these 
macrophages correspond with Th1 and Th2 responses (58, 69), both M1 and M2 
macrophages are critical to the immune response. Additionally, M2 macrophages may 
play a role in maintaining homeostasis throughout the body. 
 
III. Helicobacter 
A. General Information 
Helicobacter, a gram negative, spiral, motile bacterium, is the causative agent of 
ulcers, peptic ulcer diseases, hepatic cancer, and many intestinal diseases ((201, 202) 
reviewed in (203, 204)). Helicobacter infection is difficult to detect because less than 
30% of infections exhibit clinical symptoms (201). H. pylori is the most common human 
pathogenic form with more than 50% of the world’s population thought to be infected 
(reviewed in (203, 204)). In some parts of the world, up to 80% of the population is 
infected by the age of 10 (202).  
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Helicobacter is also a common intestinal pathogen of laboratory mice. Many 
colonies are not routinely screened for Helicobacter and the infection remains undetected 
due to a lack of or mild symptoms. A recent study confirmed that 88% of mice from 
commercial and academic sources worldwide tested positive for Helicobacter (205). 
Exposure to dirty bedding transmits Helicobacter to mice through fecal-oral contact 
(reviewed in (206)). After infection with Helicobacter, which normally colonizes the 
lower intestinal tract of rodents such as mice, rats, gerbils and hamsters, most animals 
remain asymptomatic for long periods of time. However, a few strains of mice develop 
colitis that may result in rectal prolapse (206). Previously, Helicobacter infection was not 
believed to influence most experiments. However, recent evidence indicates that 
Helicobacter infection induces inflammation in mice with no disease symptoms (206). 
 
Helicobacter is detected in animal facilities by culture methods, histopathology, 
and/or polymerase chain reaction (PCR) (reviewed in (206)). The conditions required for 
culture of the bacterium are difficult and labor intensive. Histological examination of the 
liver, colon and intestine is not an effective method since not all infected mice develop 
disease. As a result, PCR for the conserved Helicobacter 16s rRNA gene isolated from 
feces is most often used due to the sensitivity and relative ease of screening (207).  
 
Eradication of infection in animal colonies has proven to be a challenge. 
Commonly used methods include restocking with Helicobacter-free animals, fostering, 
and embryo transfer ((208, 209), reviewed in (206)). Antibiotics administered in the 
drinking water is not effective in eliminating Helicobacter (210). However, amoxicillin 
or tetracycline in combination with metronidazole and bismuth given by oral gavage 
three times daily for 2 weeks was successful in treating H. hepaticus infected mice (210, 
211). Though individual antibiotics were not effective, this combined treatment also 
prevented hepatitis and typhlitis disease symptoms in immunocompromised mice (212). 
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B. Species 
H. hepaticus and H. rodentium are two strains commonly found in laboratory 
mice. H. hepaticus, first isolated from the livers of mice with chronic hepatitis, is a 
urease-positive enterohepatic bacterium (213). It induces gastrointestinal track tumors 
(214, 215), inflammatory bowel disease (216-218), colitis (219, 220), chronic hepatitis 
(214, 221), and liver necrosis (215) in susceptible strains of mice. Studied susceptible 
strains include IL-10 knockouts (219), A/JCr mice (reviewed in (222)), germ-free mice 
(223) and other immunodeficient and tumor suppressor-deficient mice (218, 220). The 
pathogenesis of H. hepaticus may be due to the presence of a cytolethal distending toxin 
which causes cellular distention and cell cycle arrest, actin accumulation, morphologic 
alterations and death of HeLa cell monolayers in vitro (224, 225). Though expressing 
active urease similar to that of H. pylori, the role of urease in H. hepaticus infection is 
unknown (226). Potential roles include stimulation of phagocyte chemotaxis, immune 
cell activation, induction of cytokines, and improving survival during passage through the 
stomach (226). Urease also produces ammonia which, in addition to being a source of 
nitrogen for protein biosynthesis, may damage host cells leading to increased 
pathogenesis (226). 
 
Helicobacter rodentium was the first urease-negative Helicobacter species 
isolated from mouse intestines (227). Since it appears to be part of the normal intestinal 
flora, the pathogenic potential of H. rodentium is unknown (227). H. rodentium infection 
alone does not induce development of any clinical disease symptoms, although it can 
cause diarrhea in immunocompromised mice in conjunction with H. bilus (228). In 
addition, co-infection with H. hepaticus and H. rodentium is associated with exacerbated 
hepatitis and altered gene expression in immunocompromised mice (229).  
 
By altering the microenvironment of the stomach, intestine and colon as well as 
surrounding tissues such as the pancreas, Helicobacter may alter the phenotype of 
macrophages present in these tissues. In response to H. hepaticus infection, 
thioglycollate-elicited peritoneal macrophages produce high levels of IL-6, KC and 
MCP-1 (230). Co-infection with H. hepaticus and H. rodentium causes a significant 
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increase in IP-10, MIP-1α, and IL-10 mRNA levels in the cecum (229). Though it is 
unclear which cells are responsible for this increase, macrophages are the likely source 
since Helicobacter induces production of cytokines by macrophages in vitro (230). 
Surprisingly, this activation occurs through TLR2, not TLR4 as expected with gram 
negative bacteria (230). This may occur due to the abnormal structure and composition of 
Helicobacter LPS (231). 
 
Upon examination, Muotiala et. al. found that the unusual phosphorylation pattern 
and acylation of lipid A in Helicobacter LPS led to decreased biological activity (231). 
Specifically, H. pylori LPS has 1000 fold less mitogenic and pyrogenic activity and 500 
fold lower lethal toxicity than Salmonella typhimurium LPS (231). The resulting minimal 
local inflammatory response is likely advantageous to the bacterium and may contribute 
to the persistence of the infection (232). 
 
H. pylori LPS also expresses Lewis x and Lewis y blood group antigens similar to 
those normally found in the gastric mucosa (233). Administering H. pylori-induced anti-
Lewis structure monoclonal antibodies resulted in gastritis in mice which suggests a 
pathogenic function for these antibodies (233). This may provide a mechanism for H. 
pylori-associated gastritis and other Helicobacter-related autoimmune diseases (233). 
Th1 cellular immune responses contribute to Helicobacter-associated hepatitis (234) and 
gastritis with exacerbated disease (235). A strong Th2 response results in a dramatically 
decreased bacterial load which may play a role in protection from disease or control of 
the infection (235). Since Th2 responses dominate in the intestine, this process may 
contribute to the persistent nature of Helicobacter infections and the lack of clinical 
symptoms in most patients. 
 
Though it is currently unknown which cell types are responsible for elevated 
cytokine production in the gut during Helicobacter infection, macrophages may be the 
source. Resident macrophages play a role in maintaining the unresponsive Th2 
environment of the intestine and surrounding muscle layers by producing a range of 
cytokines and chemokines. Helicobacter alters the expression of such factors by 
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macrophages in vitro (230). As a result, Helicobacter likely also affects gene expression. 
Altering gene expression may alter macrophage phenotype and function as well. 
Therefore, we hypothesized that Helicobacter infection alters the phenotype and 
inflammatory response of submucosal intestinal macrophages. 
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CHAPTER 2 - Helicobacter Infection Alters the Phenotype and 
Inflammatory Response of Mouse Intestinal Muscle 
Macrophages 
Introduction 
Helicobacter is a common intestinal pathogen of laboratory mice with 88% of 
mice from both commercial and academic sources worldwide testing positive for one or 
more Helicobacter species (205). H. hepaticus and H. rodentium are two species 
commonly found in research related rodents. In susceptible mice, H. hepaticus induces 
hepatitis and subsequent liver necrosis and tumors (reviewed in (222)) as well as 
intestinal inflammation and pro-inflammatory cytokine production (229). The 
development of disease symptoms may be due to the unusual composition and biological 
activity of Helicobacter lipopolysaccharide (LPS) (231) which likely contributes to the 
persistence of the infection (232). In contrast, H. rodentium appears to be part of the 
normal intestinal flora, and infection does not induce development of any clinical disease 
symptoms (227). However, in conjunction with other Helicobacter species including H. 
hepaticus and H. bilus, H. rodentium exacerbates hepatitis, alters gene expression (229), 
and induces diarrhea (228) in immunocompromised mice.  
 
Intestinal macrophages may play a role in the response to Helicobacter infection. 
The innate immune response to other bacterial LPS is largely mediated by macrophages 
(230, 236), the largest population of which is found in the intestine (116). In the 
muscularis layers surrounding the intestine, macrophages form a regularly distributed 
network of cells (36, 121, 122). The function of these macrophages in response to 
infection has not been defined. In vitro studies categorize macrophage activation into two 
types: classically or alternatively activated. Classically activated macrophages, also 
known as type 1 (M1) macrophages, secrete pro-inflammatory cytokines and support Th1 
responses (69). Alternatively activated macrophages, also known as type 2 (M2) 
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macrophages, secrete anti-inflammatory factors and play a role in regulating cellular 
immunity and homeostasis (69, 102). Specific genes identify M1 and M2 macrophages. 
M1 macrophages express inducible nitric oxide synthase (iNOS) , interleukin 12 (IL-12) 
and tumor necrosis factor α (TNF-α) (75). In contrast, M2 macrophages express 
Arginase-1 (Arg-1), Fizz-1 (found in inflammatory zone-1), sphingosine kinase-1 (Sk-1), 
and/or Ym-1 (54, 75, 104, 107, 237). 
 
Recent studies investigated intestinal muscularis macrophages; however, there 
was not a consensus as to the phenotype or function of intestinal macrophages (36, 37, 
117-124). Human intestinal macrophages isolated by enzyme digestion lack CD14 and do 
not produce IL-1, IL-12 or TNF-α in response to LPS (117-119). However, macrophages 
allowed to migrate out of the intestine do express CD14 and produce TNF-α in response 
to LPS (120) suggesting that isolation methods may alter phenotype. Macrophages 
isolated from whole mouse intestine by enzyme digestion express low levels of F4/80 and 
MHC II (124) as determined by flow cytometry. In contrast, macrophages isolated from 
only the intestinal muscle express high levels of F4/80 and MHC II as determined by 
immunohistochemistry (IHC) and also take up Fitc dextran (37). The disparities in 
observed phenotypes may be due to isolation of macrophages from different intestinal 
tissues using a variety of separation and digestion methods. The difference may also be 
associated with the method used to examine surface marker expression. Nevertheless, the 
observed intestinal macrophage phenotypes do not coincide with that of pro- or anti-
inflammatory macrophages.  
 
By altering gene expression and cytokine production in the microenvironment of 
the stomach, intestine and colon (229), Helicobacter may alter the phenotype of 
macrophages present in these and the surrounding tissues. Though it is unclear which 
cells are responsible for producing Helicobacter-induced pro-inflammatory cytokines in 
vivo (229), macrophages are the likely source since Helicobacter induces cytokine 
production by macrophages in vitro (230, 238, 239). Therefore, we hypothesize that 
Helicobacter infection alters the phenotype and inflammatory response of submucosal 
intestinal macrophages.  
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To test this hypothesis we examined macrophages present in whole mounts of 
intestinal muscle as well as isolated macrophages to determine the effects of Helicobacter 
infection. Increased expression of F4/80 in both whole mounts and isolated cells suggests 
Helicobacter infection may induce macrophage maturation. Infection also alters 
constitutive gene expression. Macrophages from the intestinal muscle of Helicobacter-
infected mice express Sk-1, TNF, and significantly more Fizz-1 than macrophages from 
uninfected mice. The effects of Helicobacter can also be seen in cultured intestinal 
muscle macrophages. Cultured macrophages from Helicobacter-infected mice 
significantly increase phagocytosis but constitutively produce less IP-10. In addition, 
Helicobacter infection alters the response to stimuli. Interestingly, macrophages from 
infected mice show a decreased response to stimulation with either LPS or IC, producing 
significantly lower concentrations of cytokines, chemokines, and PGE2. These data show 
that the intestinal muscle macrophage phenotype, function and response to stimulation 
are altered by Helicobacter infection both in vivo and in vitro. However, the mechanism 
by which this occurs remains unknown. 
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Materials and Methods 
Mice 
C57Bl/6J mice were purchased from The Jackson Laboratory (Bar Harbor, 
Maine) and maintained in the Kansas State University Division of Biology rodent facility 
(Manhattan, KS). Animals were given rodent chow and water ad libitum and housed in 
12h light/dark cycles. All procedures were approved by the Institutional Animal Care and 
Use Committee. Research was conducted in compliance with the Animal Welfare Act 
and other federal statutes and regulations relating to animals and experiments involving 
animals. Experiments were performed according to the principles set forth in the Guide 
for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 
National Research Council, 1996 edition). 
Tissue Culture 
The J774A.1 macrophage cell line was grown in Dulbecco's Modified Eagle's 
Medium (DMEM, Atlanta Biologicals) containing 5% fetal bovine serum (FBS, Atlanta 
Biologicals), 5% NuSerum (BD Biosciences) and 1% L-Glutamine (Gibco) at 37°C with 
8% CO2.  
Macrophage Isolation and Culture 
Intestinal macrophages were isolated from 2-4 mo old infected or uninfected 
C57Bl/6J mice using a method adapted from Klaff et. al (36). Jejunum and ileum were 
removed from euthanized mice and placed in ice cold, Ca++ and Mg++ free Hanks 
balanced salt solution (HBSS, Cellgro). The intestine was flushed, cut into 1-2 inch 
segments, and placed in fresh Ca++ and Mg++ free HBSS on ice. Segments were slipped 
onto a 3.25-3.5mm knitting needle and the mesentery removed. The muscularis was 
gently incised along the mesenteric border and circumferentially stripped from the 
mucosa. Muscle tissue was minced and placed in digestion medium containing 1 mg/ml 
collagenase (Worthington) in Ca++ and Mg++ free HBSS supplemented with 0.4 mM 
CaCl2 (Allied Chemical). Tissue was digested at 37°C for 30 min and pelleted by 
centrifugation at 1200 rpm for 10 min. The pellet was washed once with DMEM 
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containing 2% serum then once with serum-free OptiMEM (Gibco). The resulting pellet 
was resuspended in MΦ Medium (DMEM containing 5% FBS, 5% NuSerum, 10% 
OptiMEM, 5 ng/ml recombinant mouse M-CSF (R&D Systems), 1% L-Glutamine, 100 
U/ml penicillin G, 100 μg/ml streptomycin, and 50 μg/ml gentamicin (Gibco) then placed 
in 24 well plates. The plates were incubated at 37°C with 8% CO2 overnight. Non-
adherent cells were removed, fresh medium was added, and the remaining cells were 
cultured for up to 1 wk without changing the medium. Some sets of macrophages were 
cultured in MΦ Medium with the addition of 2 μl/ml of FibrOut (Chi Scientific), a 
reagent that prevents fibroblastic growth. Bone marrow derived macrophages were 
isolated from femurs of uninfected mice, red blood cells lysed using ACK lysis buffer 
(0.15M NH4Cl (Fisher), 10mM NaHCO3 (Fisher), 0.1mM disodium EDTA (Sigma) in 
dH2O at pH 7.3), plated in MΦ Medium at 1x105 cells per well in 24 well plates and 
grown at 37°C with 8% CO2 for up to 7 days without changing the medium. 
Thioglycollate-elicited peritoneal macrophages were obtained by peritoneal lavage from 
mice injected with 1ml of thioglycollate 3-4 days prior. Cells were plated at 1x105 cells 
per well in 24 well plates, allowed to adhere 1hr at 37°C, then used immediately.  
Stimulation 
Isolated macrophages pooled from 2-4 mice per set of stimulations were primed 
for 18h with fresh medium containing 30 U/ml interferon-γ (IFN-γ) (Sigma), 100 U/ml 
IL-4 (Antigenix), or medium alone then stimulated 18h with 10 μg/ml Escherichia coli 
LPS O55:B5 (Sigma), 150 μg/ml IgG-opsonized ovalbumin (OVA) immune complexes 
(IC), or medium alone. Supernatants were collected, centrifuged to remove cellular 
debris, and stored at -80°C until use. Bone marrow derived macrophages or 
thioglycollate-elicited peritoneal macrophages were used as a control for all stimulations. 
IgG-OVA IC was made as previously described (75, 102) by mixing a 10-fold molar 
excess of rabbit anti-OVA antibody (Bethyl Laboratories) to OVA (Calbiochem) for 30 
min at RT.  
Nitrite Determination 
Nitrite concentration was determined in supernatants generated above using 
Griess reagent (1% sulfanilamide, 0.1% napthylethylene diamine dihydrochloride, 2% 
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H3PO4 (all from Sigma) in dH2O). One hundred microliters of sample or standard (250-
1.95 μM) was incubated with 100 μl Griess reagent for 10 min at RT. The OD550 was 
determined using a Model 860 microplate reader (Bio-Rad) and compared to a standard 
curve of NaNO2 to determine concentration of nitrite in μM/ml.  
Cytokine/Chemokine Production  
Supernatants generated above were assayed for cytokine and chemokine 
production with a Lincoplex kit (Millipore) containing IFN-γ, interleukin 10 (IL-10), IL-
12, IL-1α, IL-6, interferon-inducible protein 10 (IP-10), keratinocyte-derived cytokine 
(KC, the mouse homolog of IL-8), monocyte chemotactic protein-1 (MCP-1), 
macrophage inflammatory protein-1α (MIP-1α), and tumor necrosis factor-α (TNF-α) 
bead sets according to manufacturer’s instructions. The plate was read on a Luminex100 
machine and results analyzed with MiraiBio software (MiraiBio) subtracting fresh 
medium as a blank. IL-6 and IL-10 production were also determined using ELISA kits 
(IL-6: BioLegend, IL-10: eBioscience). 
PGE2 and LTB4 Production 
Prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) production was measured in 
supernatants generated above using enzyme immunoassay (EIA) kits (Cayman Chemical) 
according to manufacturer’s instructions. Plates were read using a Model 860 microplate 
reader and analyzed using software provided. 
Limulus Amoebocytelysate Assay 
Limulus amoebocytelysate assay (LAL, Hycult Biotechnology) was performed 
using supernatants generated above according to manufacturer’s instructions. Plates were 
read using a Model 860 microplate reader and compared to a standard curve of LPS to 
determine concentration in ng/ml. 
FITC Conjugation of Zymosan 
Zymosan A particles from Saccharomyces cerevisiae (Sigma) were reconstituted 
in normal saline, activated by boiling for 1 hour, then washed with PBS. In 0.2M sodium 
carbonate/bicarbonate buffer (pH 9.6), 1 mg free fluorescein isothiocyanate (FITC, 
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Sigma) was added to10 mg zymosan and rotated in the dark for 30 min at RT. Labeled 
zymosan was then washed over a 0.45 um spin filter with PBS 3 times to remove any 
unbound free FITC. Zymosan particles were washed off the filter and resuspended in 
PBS. Fluorescent conjugation was verified using a Nikon eclipse 80i fluorescent 
microscope containing a FITC filter cube. 
Phagocytosis 
Isolated macrophages were removed from the plate by incubating with 0.06% 
EDTA for 20 min at 37°C followed by vigorous pipeting. The cells were then washed 
with Ca++ and Mg++ free HBSS containing 2% fetal bovine serum and 0.4 mM CaCl2. In 
2ml microcentrifuge tubes, macrophages were mixed with FITC-conjugated zymosan 
particles at a ratio of 10 particles per cell in Ca++ and Mg++ free HBSS containing 5% 
normal mouse sera. With 1x105 cells per group, the experimental group was incubated 
rotating at 37°C for 20 min. To control for particles attached to the cell surface, another 
group was incubated rotating at 37°C for 20 min then treated with trypsin for 10 min 
rotating at 37°C to remove external particles. To inhibit phagocytosis, a third group was 
incubated on ice for 20 min and shaken every 5 min. Cells were washed with Ca++ and 
Mg++ free HBSS. Cytospins were prepared using 1x105 cells and fixed in methanol. 
Fluorescence was visualized on a Nikon eclipse 80i fluorescent microscope containing a 
FITC filter cube, photographed with a CoolSnap CF camera (Photometrics), and analyzed 
using Metavue software (Molecular Devices). At least 100 cells per slide were scored and 
phagocytic index (total # particles ingested/100 cells scored) and % phagocytosis (# cells 
ingesting at least 1 particle/total # cells scored) were calculated. The macrophage cell line 
J774A.1 was used as a positive control in all experiments. 
Immunohistochemistry 
Immunohistochemistry was performed on either whole muscle mounts or 
cytospins. Whole muscle mounts from C57Bl/6 mouse intestine were stripped from the 
mucosa, placed in chamber slides, and fixed in acetone. Isolated cells were removed from 
the plate, prepared as cytospins, and fixed in methanol. All samples were blocked with 
10% sera (Jackson ImmunoResearch) from the host of the secondary antibody in PBS for 
30 min at 37°C then incubated with primary antibody overnight at 4°C (Table 2). Slides 
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were washed and incubated with secondary antibody as needed for 1 hour at RT or 
fluorescent-conjugated strepavidin for 15 min at RT. Fluorescence was visualized on a 
Nikon eclipse 80i fluorescent microscope, photographed with a CoolSnap CF camera, 
and analyzed using Metavue software. Relative fluorescence of immunohistochemical 
staining was quantified using Image J (NIH). The threshold was set to zero based on the 
isotype control and the total positive area measured. 
 
Table 2. IHC Antibodies 
Antibody Isotype Concentration Fluorochrome/2° 
CD11b1 Rat IgG2b 2.5 μg/section Purified (Pur)/αRat IgG-FITC 
F4/801 Rat IgG2a 2.5 μg/section Pur/αRat IgG-FITC 
IL-62 Rat IgG1 0.5 μg/section Pur/αRat IgG-FITC, -Texas Red 
αRat IgG3  0.375 μg/section -FITC, -Texas Red 
1 eBioscience, 2Biolegend, 3Jackson ImmunoResearch 
 
Flow Cytometry 
Isolated macrophages were removed from plate by incubating with 0.06% EDTA 
for 20 min at 37°C followed by vigorous pipeting. The cells were washed in staining 
buffer (Ca++ and Mg++ free HBSS containing 2% fetal bovine serum and 0.4 mM CaCl2) 
then incubated with FcR block (Table 3) for 15 min on ice. Primary antibody or 
appropriate isotype control (Table 3) was added in a volume of 100 μl for 15 min on ice. 
Secondary antibodies (Table 3) were used as required by incubation for 15 min on ice 
after washing with staining medium. Cells were washed twice and resuspended in 200 μl 
staining buffer for analysis. Data was collected without compensation using a 
FACSCalibur flow cytometer equipped with 488 nm and 635 nm lasers (BD 
Biosciences). Analysis was performed using WinList software (Verity Software House) 
with compensation set by N-Color compensation with HyperLog transformation. The 
macrophage cell line J774A.1 was used as a control in all experiments. 
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Table 3. Flow Cytometry Antibodies 
Antibody Isotype Concentration Fluorochrome/2° 
Fc Block1  1 μg/105 cells Purified (Pur) 
CD11b2 Rat IgG2b 0.4 μg/105 cells APC 
CD143 Mouse IgG1 0.2 μg/105 cells Alexa 488 
CD361 Mouse IgA 1 μg/105 cells Pur/αIgA-FITC 
CD834 Rat IgG1 0.4 μg/105 cells PE 
CD1154 Rat IgG2a 1 μg/105 cells Biotin/SA-PE 
F4/804 Rat IgG2a 1 μg/105 cells FITC 
Pan Endo1 Rat IgG2a 1 μg/105 cells Biotin/SA-APC 
Gr-11 Rat IgG2b 1 μg/105 cells FITC 
MHC II1 Mouse IgG2b 0.4 μg/105 cells PE 
TLR42 Rat IgG2a 1 μg/105 cells Biotin/SA-APC 
SA-APC4  0.2 μg/105 cells APC 
SA-PE3  0.15 μg/105 cells PE 
αIgA3  0.2 μg/105 cells FITC 
1 BDPharmingen, 2 Biolegend, 3 Caltag, 4 eBioscience 
 
mRNA Isolation  
TRIzol reagent (Invitrogen) was used to isolate total RNA from 0.5-1x106 
macrophages. Cells were incubated at RT with TRIzol, chloroform extracted, then 
centrifuged 15 min at 4°C. The upper aqueous phase containing the RNA was removed to 
a new tube, precipitated with isopropyl alcohol at RT then pelleted. The RNA pellet was 
washed with 75% ethanol, air dried, resuspended in RNase free H2O and stored at -80°C 
until use. 
cDNA Synthesis 
cDNA was synthesized from isolated mRNA using a Superscript III first strand 
synthesis kit (Invitrogen) or using M-MLV RT (Promega). One microgram mRNA was 
mixed with 1 μl random hexamers and 1 μl 10mM dNTPs in DNase and RNase free 
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water and incubated at 65°C for 5 min then moved to ice. Two microliters 10X reaction 
buffer, 4 μl 25mM MgCl2, 2 μl 0.1M DTT, 1 μl RNase out, and 1 μl RT were added to 
the RNA and incubated in a Mastercycler (Eppendorf) 10 min at 25°C, 50 min at 50°C, 5 
min at 85°C then held at 4°C. The cDNA was then incubated at 37°C with 1 μl RNase H 
to remove RNA, diluted with dH2O, and stored at -20°C until use. 
Helicobacter Detection 
Fecal samples were collected from separately housed infected or uninfected 
C57Bl/6 mice and assayed immediately or stored at -80ºC until use. Total DNA was 
isolated according to manufacturer’s instructions using a QIAmp DNA stool kit (Qiagen) 
and stored at -20°C until use. The species of Helicobacter infecting our mice were 
determined to be H. hepaticus and H. rodentium by an outside source (Research Animal 
Diagnostic Laboratory, University of Missouri). 
PCR 
PCR was performed using 5 μl 10X reaction buffer containing 15mM MgCl2, 1 μl 
50mM MgCl2, 1 μl 10mM dNTPs, 80 ng each of forward and reverse primers (Integrated 
DNA Technologies) (Table 4), and 0.5 μl Taq polymerase (Bioline) were added to 0.5 μg 
DNA or cDNA in a final volume of 50 μl and incubated for 35 cycles (30 sec at 94°C, 30 
sec at Tm (Table 4), 60 sec at 72°C) in a Mastercycler then stored at -20°C until used. 
Samples were run on a 2% agarose gel containing 0.0001% ethidium bromide and 
visualized using an AlphaImager (AlphaInogen). GAPDH sequence was obtained from 
Barber et.al. (240), iNOS primer sequence was obtained from Manthey et. al. (241), 
Helicobacter 16S rRNA primer sequence was obtained from Riley et. al. (242), all other  
primer sequences were designed using IDT PrimerQuest;. Relative intensity of PCR 
bands were quantified using Image J (NIH) and normalized to GAPDH.  
 
Table 4. Primer Sequences 
Gene Primer sequence Tm 
Arg-1 Fwd 5’ ACC TGG CCT TTG TTG ATG TCC CTA 3’ 54°C
 Rev 5’ AAG GTC TCT TCC ATC ACC TTG CCA 3’  
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CD3 Fwd 5’ AGA GGA TGC GGT GGA ACA CTT TCT 3’ 60°C
 Rev 5’ ACT CAC ACA CTC GAG CTT TCA GGT 3’  
COX-2 Fwd 5’ ATC CTG CCA GCT CCA CCG 3’ 54°C
 Rev 5’ TGG TCA AAT CCT GTG CTC ATA CAT 3’  
Fizz-1 Fwd 5’ TCC AGC TGA TGG TCC CAG TGA ATA 3’ 54°C
 Rev 5’ AAG CTG GGT TCT CCA CCT CTT CAT 3’  
GAPDH Fwd 5’ CCA TGG AGA AGG CCG GGG 3’ 54°C
 Rev 5’ CAA AGT TGT CAT GGA TGA CC 3’  
IL-12p40 Fwd 5’ CGT GCT CAT GGC TGG TGC AAA 3’ 60°C
 Rev 5’ GAA CAC ATG CCC ACT TGC TG 3’  
iNOS Fwd 5’ CCC TTC CGA AGT TTC TGG CAG CAG C 3’ 65°C
 Rev 5’ GGC TGT CAG AGC CTC GTG GCT TTG G 3’  
IRAK-M Fwd 5’ TAC AGT GCA CAA ATG GCA CAA CCC 3’ 60°C
 Rev 5’ TTA ACT TGG CCT TCG TTG CCA CAC 3’  
SIGIRR Fwd 5’ TGA AAG ATG GTC TGG CAT TGG 3’ 54°C
 Rev 5’ TCG CCA AAG AGT GAA GGA AT 3’  
Sk-1 Fwd 5’ ATG GTC TGA TGC ATG AGG TGG TGA 3’ 54°C
 Rev 5’ ACC ACA GTC CAA TGA GAA GGC ACT 3’  
ST2 Fwd 5’ ACA CTT GTC AAT TCA CAC ACG CGG 3’ 60°C
 Rev 5’ TAA TCT GCC ACA GGA CAT CAG CCA 3’  
TLR4 Fwd 5’ GTA TAT GTG AAC ATC AGA AAT TCC T 3’ 58°C
 Rev 5’ CAT GTT TGA GCA ATC TCA TAT TCA A 3’  
TNF Fwd 5’ GGG ATG AGA AGT TCC CAA ATG 3’ 54°C
 Rev 5’ CTC CAG CTG GAA GAC TCC TCC CAG 3’  
Ym-1 Fwd 5’ TTC CAA GGC TGC TAC TCA CTT CCA 3’ 54°C
 Rev 5’ AGA CCA CGG CAC CTC CTA AAT TGT 3’  
Helicobacter Fwd 5’ CTA TGA CGG GTA TCC GGC 3’ 54°C
16S rRNA Rev 5’ ATT CCA CCT ACC TCT CCC A 3’  
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Statistics 
Statistical analyses were performed using the Student’s t test with significance set 
at a P value less than 0.05. GraphPad Prism software (GraphPad Software) was used to 
conduct all analyses. Numbers in the text are shown as mean ± standard error of mean 
(SEM). 
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Results 
Due to the large number of research-associated mice that are infected with 
Helicobacter, approximately 88% worldwide (reviewed in (206)), the effects of this 
infection on the intestine need to be identified. The intestinal muscle contains a network 
of macrophages whose phenotype and function are still not well understood (36, 37, 117-
124). This study analyzed the effects of Helicobacter infection on the phenotype and 
function of mouse intestinal muscle macrophages. Initially, we determined the phenotype 
of intestinal muscle macrophages by examining surface marker expression, gene 
expression, cytokine and chemokine production, as well as arachidonic acid and arginine 
metabolism. With the establishment of the intestinal muscle macrophage phenotype, we 
investigated the effects Helicobacter infection on these cells.  
Helicobacter infection is detected in fecal samples by RT-PCR 
To assess the infection status of the mice used in these studies, the amount of the 
Helicobacter 16S rRNA gene in fecal samples was examined by RT-PCR (Fig. 1A) and 
compared to a known positive control. All samples from infected mice contained similar 
amounts of the Helicobacter 16S rRNA gene when compared to the known infected 
control (Fig 1B). Conversely, the Helicobacter 16S rRNA gene was not detected in any 
of the separately housed, uninfected mice used in these studies (Fig 1A and 1B).  
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Figure 1. Helicobacter was detected in fecal samples from infected C57Bl/6 mice.  
Fecal samples were collected from Helicobacter-infected (■) or uninfected (□) mice, total 
DNA isolated and Helicobacter 16S rRNA gene detected by PCR as described. (A) 
Representative samples shown from Helicobacter-infected or uninfected mice. Control is 
a fecal sample from a known positive mouse. (B) Percent of bacterial DNA for the 16S 
rRNA gene compared to a known positive control set at 100, shown in arbitrary units. 
n=3-4 cages of mice per group, ND-none detected. 
 
Macrophages from Helicobacter-infected mice have altered surface marker 
expression 
Surface marker expression identifies and determines maturation state of 
macrophages. Whole mounts of intestinal muscle were isolated from C57Bl/6 mice and 
stained for F4/80, a marker of mature macrophages, and CD11b, an integrin present on 
most macrophages. Macrophages present in the intestinal muscle possess a stellate 
structure and form a network of cells as indicated by expression of F4/80 (Fig. 2A). 
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CD11b was also expressed (Fig. 2B), but the staining intensity was lower than F4/80. 
Both markers were positive when compared to isotype control stained sections (Fig. 2C). 
The staining was quantified as indicated and expression of F4/80 found to be 
significantly higher than CD11b (Fig. 2G, white bars). Therefore, the intestinal muscle 
contains a population of mature F4/80+ macrophages and a similar population that 
expresses CD11b. 
 
We hypothesized that Helicobacter infection would alter the surface marker 
expression of macrophages present in the intestinal muscle. Whole mounts of intestinal 
muscle were isolated as described and stained for F4/80 and CD11b. Macrophages 
present in the intestinal muscle of infected mice (Fig. 2D-F) stained more intensely than 
those from uninfected mice (Fig. 2A-C) for both F4/80 (Fig. 2A and 2D) and CD11b 
(Fig. 1B and 1E) when compared to appropriate isotype controls (Fig. 2C and 2F). Upon 
quantification, F4/80 expression was almost 4 fold higher and CD11b almost 10 fold 
higher in whole muscle mounts from infected mice compared to those from uninfected 
mice (Fig. 2G). As no increase in overall cell number was observed (data not shown), 
these data suggest that intestinal muscle macrophages may be maturating in response to 
Helicobacter infection.  
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Figure 2. Helicobacter infection increases F4/80 and CD11b expression by intestinal 
muscle macrophages. 
(A-F) Whole mounts of intestinal muscle were stripped from mucosa of uninfected (A-C) 
or infected (D-F) mice, and stained with F4/80 (A and D), CD11b (B and E), or 
appropriate isotype control (C and F). Photomicrographs are representative of at least 3 
experiments. (G) Relative fluorescence of immunohistochemical staining from uninfected 
(□) or infected (■) mice was quantified using Image J. The threshold of the isotype 
control was set to zero and the total positive area measured. n=3-4 experiments with 4-6 
representative photos analyzed per treatment, *p<0.05 infected compared to uninfected. 
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Macrophages from Helicobacter-infected mice have altered gene expression 
To determine the phenotype of these macrophages, both pro-inflammatory and 
anti-inflammatory genes were investigated. Pro-inflammatory macrophages express IL-
12, TNF-α, and iNOS mRNA (69, 75), while anti-inflammatory macrophages express 
mRNA for one or more of the genes Fizz-1, Sk-1, Arg-1, and Ym-1 (54, 75, 104, 107, 
237). Macrophages directly isolated from the intestinal muscle of normal mice expressed 
low levels of mRNA for the gene Fizz-1 as determined by RT-PCR (Fig. 3A and C). 
However, macrophages produced almost no detectable amounts of Sk-1, Ym-1 or Arg-1 
mRNA. Expression of these genes is significantly lower than anti-inflammatory, control, 
bone marrow-derived macrophages (BMMΦ) cultured in M-CSF and stimulated with IL-
4 and IC (Fig. 3A). Intestinal muscle macrophages expressed little to no IL-12, TNF-α, or 
iNOS mRNA (Fig. 3B and C) compared to levels observed in pro-inflammatory, control 
BMMΦ cultured in M-CSF and stimulated with LPS and IFN-γ (Fig. 3B). Figure 3C 
(white bars) shows the quantification of band intensity. 
 
Since some surface markers were altered with infection, we hypothesized that 
Helicobacter may alter gene expression as well. To test this, we analyzed macrophage 
gene expression. As determined by RT-PCR, macrophages directly isolated from the 
intestinal muscle of infected mice expressed high levels of Fizz-1, similar to that seen in 
control macrophages (Fig. 3A). Upon quantification, macrophages from infected mice 
expressed significantly higher levels of Fizz-1 compared to those from uninfected mice 
(Fig 3C). Unlike macrophages from uninfected mice, Sk-1 and TNF were expressed by 
macrophages from infected mice in addition to low levels of Arg-1 (Fig. 3). Neither 
macrophages isolated from uninfected nor Helicobacter-infected mice expressed 
appreciable amounts of Ym-1, IL-12, or iNOS (Fig. 3). Sk-1 and TNF expression by 
macrophages from infected mice is similar to that seen in control macrophages, but Ym-1, 
Arg-1, and iNOS expression is significantly lower than controls (Fig 3). Taken together 
these data suggest that Helicobacter infection may induce macrophages present in 
intestinal muscle to become more mature and alter gene expression in vivo.  
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Figure 3. Helicobacter infection increases some gene expression by intestinal muscle 
macrophages. 
Total RNA was isolated from intestinal muscle macrophages and (A) Fizz-1, Sk-1, Ym-1, 
Arg-1, (B) IL-12, iNOS, TNF, and GAPDH transcripts were determined by RT-PCR. 
BMMΦ stimulated with IL-4 and IC were used as anti-inflammatory controls (A) or 
stimulated with IFN and LPS as pro-inflammatory controls (B). (C) Relative intensity of 
PCR bands from uninfected (□) or Helicobacter-infected (■) mice were quantified using 
Image J and normalized to GAPDH. n=4-8, *p<0.05 infected compared to uninfected.  
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Helicobacter infection does not alter constitutive production of most cytokines or 
chemokines by intestinal muscle macrophages 
Macrophages are involved in numerous cellular processes and produce many 
soluble factors. F4/80 expressing macrophages in the intestinal muscle (Fig. 4A) also 
express IL-6 (Fig. 4B) as indicated by co-localization in the muscle tissue (Fig. 4C) when 
compared to isotype control (Fig. 4D). Consequently, we measured cytokine and 
chemokine production by macrophages. Freshly isolated macrophages were incubated 24 
hours without stimulation and the resulting supernatants used to analyze constitutive 
cytokine and chemokine production. We examined secreted factors associated with both 
pro-inflammatory and anti-inflammatory macrophages. Large amounts of IL-6 and low 
levels of TNF-α were detected (Fig. 5, white bars). However, when compared to pro- and 
anti-inflammatory BMMΦ controls, these were very low. Intestinal muscle macrophages 
generated significant concentrations of IP-10 as well as lower concentrations of KC (Fig. 
5, white bars). Both were also significantly lower that seen in the controls. MCP-1 was 
the only factor produced in amounts similar to those observed by the controls (Fig. 5, 
white bars). Thus, many of the products secreted by these macrophages are chemokines 
suggesting that macrophages in the intestinal muscle may play a role in regulating 
leukocyte infiltration and inflammation in the intestine.  
 
Having shown that infection alters both gene and surface marker expression, we 
investigated the effects of Helicobacter infection on the products secreted by intestinal 
muscle macrophages. Cells isolated from infected mice were used to analyze constitutive 
cytokine and chemokine production. Surprisingly, other than IP-10, none of the measured 
cytokines or chemokines produced constitutively by these macrophages were 
significantly different between those from infected or uninfected mice (Fig. 5). IP-10 
production by macrophages from infected mice was almost half that produced by 
macrophages from uninfected mice. Although there was a trend towards increased 
production of TNF-α and MCP-1 by macrophages from uninfected mice, these 
differences were not significant (Fig. 5). These data indicate that Helicobacter infection 
alone does not alter the constitutive production of most of the cytokines or chemokines 
we studied. 
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Figure 4. F4/80+ intestinal muscle macrophages also express IL-6.  
(A-D) Whole mounts of intestinal muscle were isolated from uninfected mice and stained 
with (A) F4/80, (B) IL-6, (C) both F4/80 and IL-6, (D) or appropriate isotype controls. 
Photomicrographs are representative of at least 3 experiments.  
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Figure 5. Intestinal muscle macrophages from infected and uninfected mice 
constitutively express similar levels of cytokines and chemokines. 
Intestinal muscle macrophages were isolated from uninfected (□) or Helicobacter-
infected (■) mice and cultured in medium containing M-CSF for 24 hours. Supernatants 
were collected and assayed for cytokine and chemokine production with a Lincoplex kit 
according to manufacturer’s instructions (level of detection = 3–10,000 pg/ml). BMMΦ 
cultured in M-CSF and stimulated with IFN and LPS ( ) or IL-4 and IC ( ) were used as 
controls. Results were analyzed using MiraiBio software. Each point represents the 
average of 3-7 independent experiments measuring duplicate supernatants. *p<0.05 
infected compared to uninfected. 
 
 
Helicobacter infection does not affect constitutive arginine or arachidonic acid 
metabolism in intestinal muscle macrophages 
The amino acid, arginine is an important precursor needed for immune function 
(52, 54). Pro-inflammatory macrophages metabolize arginine into nitric oxide (NO) via 
iNOS (75). Macrophages isolated from intestinal muscle do not make any detectable 
levels of NO compared to LPS and IFN-γ stimulated thioglycollate-elicited peritoneal 
macrophage controls (data not shown). Similar to macrophages from uninfected mice, 
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macrophages from infected mice did not produce NO (data not shown). In addition, 
Helicobacter infection did not stimulate a difference in NO production by thioglycollate-
elicited peritoneal macrophages (data not shown). Therefore, infection with Helicobacter 
does not stimulate the production of NO. 
 
As another important precursor, arachidonic acid is broken down into many 
inflammatory lipid mediators including LTB4 and PGE2. Produced in response to 
infection, LTB4 is a pro-inflammatory product (reviewed in (189)). PGE2, however, can 
be either pro- or anti-inflammatory depending on the concentration produced during 
infection. PGE2 is pro-inflammatory during the early stages of infection when the 
concentration is high and anti-inflammatory late in infection when concentration is low 
(reviewed in (195-197)). Intestinal muscle macrophages produced LTB4 at moderate 
levels (Fig. 6, white bars). Both pro- and anti-inflammatory control macrophages 
produced similar concentrations of LTB4 (Fig. 6). Production of PGE2 was significantly 
higher than that of LTB4 by intestinal macrophages (Fig. 6, white bars). This trend was 
also seen in the controls. Unlike most cytokines and chemokines, no difference between 
control and intestinal muscle macrophages was observed (Fig. 6). These data show that 
macrophages in the intestinal muscle constitutively produce a wide range of factors with 
varying effects.  
 
Investigation of arachidonic acid metabolites found that Helicobacter infection 
does not influence the constitutive amounts of LTB4 or PGE2 produced by intestinal 
muscle macrophages after 24 hours in culture (Fig. 6). However, though not different 
from uninfected or LPS control macrophages, cells from infected mice produced 
significantly more PGE2 than IC stimulated control macrophages (Fig. 6). These data 
indicate that Helicobacter infection alone does not influence the metabolism of arginine 
or arachidonic acid. 
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Figure 6. Helicobacter infection does not alter constitutive production of LTB4 or 
PGE2 by intestinal muscle macrophages. 
Intestinal muscle macrophages were isolated from uninfected (□) or Helicobacter-
infected (■) mice then cultured 24h in medium containing M-CSF. Supernatants were 
collected and assayed by EIA for LTB4 or PGE2. BMMΦ cultured in M-CSF and 
stimulated with IFN and LPS ( ) or IL-4 and IC ( ) were used as controls. Each bar 
represents the average of 5-7 independent experiments measuring duplicate supernatants  
 
 
Resident muscle macrophages cultured for 7 days in M-CSF retain a phenotype 
similar to freshly isolated intestinal macrophages 
To verify that the collected cells were macrophages and allow for more extensive 
studies, macrophages isolated from intestinal muscle and cultured for 7 days in medium 
containing M-CSF. We hypothesized that cultured macrophages would display a similar 
phenotype to those found in the tissue based on surface marker expression, and cytokine 
and chemokine production. Though somewhat heterogeneous, 70-75% of the cultured 
cells stained positive by IHC for F4/80 (Fig. 7A) and CD11b (Fig. 7B) when compared to 
appropriate isotype controls (Fig. 7C). In addition, we analyzed these cells flow 
cytometry. In contrast to IHC, less than 5% of the analyzed cells were positive for F4/80, 
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CD11b or TLR4. Flow cytometry also showed that less than 10% of the cells were 
positive for CD14, and less than 15% were positive for CD36 (Fig. 8, white bars). These 
numbers are extremely low when compared to J774A.1 macrophages (81±2.5% CD11b+, 
60.4±4.8% TLR4+), but consistent with those previously observed in human intestinal 
muscle macrophages (117). To ensure that the cultures were not contaminated with 
fibroblasts, macrophages were cultured with FibrOut to prevent fibroblastic growth. Flow 
cytometry showed that surface marker expression on cells cultured with FibrOut was not 
significantly different when compared to those cultured under normal conditions (data 
not shown). In addition, flow cytometric and/or PCR analysis showed that these cultures 
contained few to no dendritic cells, T cells, or endothelial cells (data not shown). These 
data demonstrate that the cells isolated from the intestinal muscle are macrophages and 
that the culture is relatively free of other contaminating cell types. 
 
Macrophages from infected mice were also analyzed for surface marker 
expression to investigate any changes in response to culture. Similar to muscularis tissue 
staining, macrophages isolated from infected mice (Fig. 7D-F) stained more intensely 
than those from uninfected mice (Fig. 7A-C) for both F4/80 (Fig. 7A and 7D) and CD11b 
(Fig. 7B and 7E) when compared to appropriate isotype controls (Fig. 7C and 7F). In 
contrast, macrophages from infected or uninfected mice displayed no difference in 
expression of F4/80, CD11b, CD14, or TLR4 when analyzed by flow cytometry (Fig. 8). 
CD36 expression was significantly lower in macrophages from infected mice; however, 
this is likely not biologically significant. Overall, these data demonstrate that the 
Helicobacter-induced increase in F4/80 and CD11b expression remains after 7 days in 
culture. 
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Figure 7. Helicobacter infection increases F4/80 and CD11b expression in cultured 
intestinal muscle macrophages. 
Macrophages were isolated from intestinal muscle of uninfected (A-C) or infected (D-F) 
mice, cultured 7 days in medium containing M-CSF, then stained with F4/80 (A and D), 
CD11b (B and E), or appropriate isotype control (C and F). Representative 
photomicrographs are shown. n=3-4 
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Figure 8. Helicobacter infection alters some surface marker expression in cultured 
intestinal muscle macrophages as determined by flow cytometry. 
Intestinal muscle macrophages were isolated from uninfected (□) or Helicobacter-
infected (■) mice then cultured 7 days in medium containing M-CSF. Cells were stained 
with the indicated antibodies or appropriate isotype control then analyzed by flow 
cytometry. n=3-4, *p=0.0597 
 
 
To confirm that culture does not change the products secreted by intestinal muscle 
macrophages, we measured cytokine and chemokine production. IL-6 and KC are shown 
as representative cytokines or chemokines, respectively. Compared to 24 hours after 
isolation, constitutive secretion of these proteins did not change after 7 days in culture 
with M-CSF (Fig. 9). Production of cytokines and chemokines by macrophages cultured 
from infected mice was also examined. Concentrations of IL-6 and KC secreted by 
macrophages from infected mice did not significantly increase or decrease after 7 days in 
culture (Fig. 9). In addition, there was no significant difference between macrophages 
from infected or uninfected mice. Overall, when compared to freshly isolated 
macrophages or those found in the tissue, macrophages isolated from intestinal muscle 
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and cultured in M-CSF expressed similar levels of surface markers, cytokines and 
chemokines. Therefore, cultured intestinal muscle macrophages have a similar 
phenotype. All further studies used intestinal muscle macrophages cultured under these 
conditions. 
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Figure 9. Isolated intestinal muscle macrophages express cytokines and chemokines 
at similar levels after 24 hours or 7 days of culture. 
Intestinal muscle macrophages were isolated from uninfected (dashed lines) or 
Helicobacter-infected (solid lines) mice and cultured in M-CSF for 7 days. Cells were 
stimulated with medium alone. Supernatants were collected and assayed for IL-6 and KC 
production with a Lincoplex kit according to manufacturer’s instructions. Results were 
analyzed using MiraiBio software. n=6-9 
 
 
Macrophages from infected mice cultured for 7 days increased phagocytic 
ability 
As well as production of factors that induce and regulate inflammation, a main 
function of macrophages is phagocytosis (reviewed in (38-40)). We hypothesized that 
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macrophages isolated from intestinal muscle would be phagocytic. Macrophages cultured 
for 7 days in M-CSF were incubated with fluorescent zymosan particles as described. To 
distinguish between external adherence of particles to the macrophages and 
internalization by phagocytosis, trypsin treatment of one of triplicate samples removed 
externally bound particles while ice inhibited phagocytosis in another of the triplicates. 
Percent phagocytosis (Fig. 10A) and phagocytic index (data not shown) were calculated 
from representative photomicrographs (Fig. 10C) of at least 100 cells per treatment per 
experiment. Approximately 25% of macrophages from the intestinal muscle 
phagocytosed zymosan particles (Fig 10A, white bars). Trypsin did not reduce the 
number of particles associated with these cells confirming phagocytosis. Treatment with 
ice resulted in a reduction in phagocytosis to 13.3 ± 3.7%. This indicates that intestinal 
macrophages are phagocytic for large particles under normal conditions. 
 
Invading pathogens activate macrophages to phagocytose foreign particles. 
Therefore, we hypothesized that macrophages from infected mice would be more 
phagocytic than those from uninfected mice. Macrophages from infected mice were three 
fold more phagocytic than those from uninfected mice with approximately 80% of the 
cells phagocytosing zymosan (Fig. 10A). Similar to above, treatment with ice resulted in 
a significant reduction in phagocytosis but did not result in complete inhibition. 
Macrophages from infected mice also ingested five times more zymosan particles per 
cell, with macrophages from infected mice containing an average of 2 particles per cell 
while those from uninfected mice contained an average of 0.4 particles per cell. These 
data show that Helicobacter infection increases the phagocytic ability of intestinal muscle 
macrophages. 
 
Due to the possibility that the presence of Helicobacter or LPS in these 
macrophage cultures could activate the cells from infected mice to have increased 
phagocytosis, we measured the amount of the Helicobacter 16S rRNA gene and total 
LPS present in the supernatants of cultured cells. Cultured macrophages from infected or 
uninfected mice did not contain the Helicobacter 16S rRNA gene (data not shown). 
Though small amounts of LPS were detected (<53.85 pg/ml), there was no difference 
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between supernatants from infected or uninfected mice. This confirms that the increase in 
phagocytosis is not due to the presence of bacteria or LPS in the macrophage cultures.  
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Figure 10. Intestinal muscle macrophages from Helicobacter-infected mice are more 
phagocytic. 
(A) Intestinal muscle macrophages isolated from uninfected (□) or Helicobacter-infected 
(■) mice were cultured for 1 wk with M-CSF. Cells were incubated 20 min with zymosan 
particles at 37°C then left untreated (cells+zym) or treated with trypsin (w/trypsin) to 
remove externally bound particles. Cytospins were prepared, photographed (B and C), 
and ≥100 cells per slide were scored. Photomicrographs are representative of 
macrophages isolated from uninfected (B) or infected (C) mice phagocytosing fluorescent 
zymosan particles. n=3-4 experiments/group, *p<0.05 infected compared to uninfected. 
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Macrophages from infected mice cultured for 7 days have decreased PGE2 
production  
To determine if culturing intestinal muscle macrophages for 7 days altered 
arachidonic acid degradation products, we examined LTB4 and PGE2 production. LTB4 
secreted by macrophages from uninfected mice remained unchanged in response to 
culture and was similar to concentrations seen in the controls (Fig. 11). In addition, 
infection did not alter LTB4 (Fig. 11) and concentrations produced were similar to the 
controls. Surprisingly, macrophages cultured from either infected or uninfected mice 
produced significantly less PGE2 after 7 days in culture (Fig. 11) when compared to day 0 
(Fig. 6). Concentrations of PGE2 produced by macrophages from infected mice were 
significantly lower than those from uninfected mice (Fig. 11). Though not significantly 
different from IC control, PGE2 production by macrophages from infected and uninfected 
mice was significantly lower than the LPS control macrophages (Fig. 11). This suggested 
that Helicobacter infection may affect expression of COX-2, which is responsible for 
inducible PGE2 synthesis. However, COX-2 was not expressed at different levels by 
macrophages from infected or uninfected mice either with (Fig. 12 and 13) or without 
(data not shown) stimulation. Therefore, both culture and infection with Helicobacter 
decreased PGE2 production by intestinal muscle macrophages without decreasing COX-2 
expression. Since macrophages cultured from intestinal muscle have similar patterns of 
surface marker expression, cytokine production and chemokine production, the decrease 
in PGE2 after culture was unexpected.  
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Figure 11. Helicobacter infection decreases constitutive PGE2 but not LTB4 
production by cultured intestinal muscle macrophages. 
Intestinal muscle macrophages isolated from uninfected (□) or Helicobacter-infected (■) 
mice were cultured 7 days in medium containing M-CSF prior to stimulation with 
medium alone. BMMΦ cultured in M-CSF and stimulated with IFN and LPS ( ) or IL-4 
and IC ( ) were used as controls. Supernatants were collected and assayed for LTB4 or 
PGE2. n=3-9, *p<0.05 infected compared to uninfected. 
 
 
Helicobacter infection does not alter gene expression in response to in vitro 
stimulation  
Different types of macrophages respond to different stimulation (69, 75). IFN-γ 
and LPS stimulate pro-inflammatory macrophages while IL-4 and immune complexes 
(IC) are a known stimuli of anti-inflammatory macrophages (69, 75). Having found that 
infection alters the phagocytic function of isolated macrophages, we hypothesized that 
Helicobacter infection would also alter the in vitro response of intestinal muscle 
macrophages to either LPS or IC stimulation. Macrophages cultured from the intestinal 
muscle of infected or uninfected mice were primed then stimulated with either IFN-γ and 
LPS or IL-4 and IC followed by examination of gene expression. With the exception of 
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PGE2, unstimulated macrophages cultured for 7 days were not significantly different 
when compared to freshly isolated (day 0) macrophages (data not shown). Therefore all 
comparisons other than arachidonic acid metabolism are made to day 0.  
 
Similar to freshly isolated intestinal muscle macrophages, no Ym-1, Arg-1, or Sk-
1 was detectable with LPS stimulation (Fig 12A and 12C, white bars) in macrophages 
from uninfected mice. Compared to day 0 (Fig. 3), macrophages stimulated with LPS 
expressed significantly decreased levels of Fizz-1. LPS stimulated macrophages also 
expressed little to no TNF-α, IL-12 or iNOS (Fig 12B and 12C, white bars). In addition, 
LPS induced a low level of COX-2 (Fig. 12B and 12C). All of these genes were detected 
in appropriately stimulated control BMMΦ (Fig. 12A and 12B). Figure 12C (white bars) 
shows the quantification of gene expression.  
 
In contrast to freshly isolated and LPS stimulated macrophages, IC stimulation 
induced intestinal muscle macrophages from uninfected mice to express low levels of 
Ym-1 and Arg-1 (Fig. 13A and 13C). Similar to LPS stimulated macrophages, IC 
stimulated macrophages expressed significantly decreased Sk-1 and Fizz-1 (Fig. 13A and 
13C) when compared to freshly isolated macrophages (Fig. 3). In addition, we observed 
TNF-α, IL-12 and iNOS at low to undetectable levels similar to that seen with LPS 
stimulation. IC induced slightly higher levels of COX-2, but there was no significant 
difference between stimulations (Fig. 13B and 13C). Gene expression was quantified as 
described and is shown in Figure 13C (white bars). These data show that IC but not LPS 
stimulates the expression of the anti-inflammatory genes Ym-1 and Arg-1 by intestinal 
muscle macrophages. This further suggests that these cells have an anti-inflammatory 
phenotype in the absence of infection.  
 
Macrophages isolated from the intestinal muscle of infected mice were also 
stimulated with LPS or IC to determine if Helicobacter infection alters gene expression. 
In response to LPS, intestinal muscle macrophages from infected mice did not express 
detectable levels of Ym-1, Arg-1, IL-12, or iNOS similar to that observed in the 
macrophages from uninfected mice (Fig. 12). LPS induced very low levels of Fizz-1, Sk-
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1, and TNF-α in macrophages from infected mice with no observed differences between 
macrophages from infected or uninfected mice (Fig. 12). As indicated above, these levels 
were significantly decreased when compared to Day 0 (Fig. 3).  
 
Macrophages from infected mice expressed low levels of Ym-1 in response to IC 
stimulation (Fig. 13A and 13C) as well as low to undetectable levels of all other genes 
examined. There was no significant difference between macrophages from infected and 
uninfected mice for any of these products (Fig. 13). These data indicate that intestinal 
muscle macrophages do not respond well to LPS or IC stimulation. However, this result 
is not due to Helicobacter infection. 
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Figure 12. Stimulation with LPS does not induce gene expression by intestinal 
muscle macrophages. 
After 7 days in culture with M-CSF, macrophages isolated from Helicobacter-infected or 
uninfected mice were stimulated with LPS and IFN-γ. Total RNA was isolated from 
intestinal muscle macrophages and RT-PCR used to determine levels of Ym-1, Arg-1, 
Fizz-1, Sk-1 (A), TNF, IL-12, iNOS, COX-2 (B), SIGIRR (C) and GAPDH (A and B) 
transcripts. BMMΦ cultured in M-CSF and stimulated with IL-4 and IC (A) or IFN-γ and 
LPS (B) were used as positive controls. Representative PCR bands shown. (C) Relative 
intensity of PCR bands from uninfected (□) or Helicobacter-infected (■) mice were 
quantified using Image J and normalized to GAPDH. n=4-7 experiments/group. 
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Figure 13. Stimulation with IC enhances expression of some genes by intestinal 
muscle macrophages. 
After 7 days in culture with M-CSF, macrophages isolated from uninfected (□) or 
Helicobacter-infected (■) mice were stimulated with IL-4 and IC. Total RNA was 
isolated from intestinal muscle macrophages, and Ym-1, Arg-1, Fizz-1, Sk-1 (A), TNF, IL-
12, iNOS, COX-2 (B), SIGIRR (C) and GAPDH (A and B) transcripts were determined by 
RT-PCR. BMMΦ cultured in M-CSF and stimulated with IL-4 and IC (A) or IFN-γ and 
LPS (B) were used as positive controls. Representative PCR bands shown. (C) Relative 
intensity of PCR bands from uninfected (□) or infected (■) mice were quantified using 
Image J and normalized to GAPDH. n=4-8 experiments/group. 
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Helicobacter infection decreases cytokine and chemokine production in 
response to in vitro stimulation 
Macrophages produce a wide range of factors in response to both pro-
inflammatory (LPS) and anti-inflammatory (IC) stimulation. To further investigate the 
intestinal muscle macrophages and their response to stimuli, cytokine and chemokine 
production as well as arachidonic acid metabolism and NO production were measured. 
As gene expression was not different after stimulation, we hypothesized that 
macrophages stimulated from infected mice would produce similar concentrations of 
cytokines and chemokines to those produced by uninfected macrophages.  
 
Intestinal muscle macrophages from uninfected mice produced significantly more 
of the cytokines, IL-6 and TNF-α, upon stimulation with LPS (Fig. 14A, white bars) than 
with IC (Fig. 14B, white bars). These values were significantly lower than appropriately 
stimulated BMMΦ controls (Fig. 14). When compared to constitutive expression, 
intestinal muscle macrophages stimulated with LPS (Fig. 14A, white bars) produced 
significantly more IL-6 than freshly isolated macrophages (Fig. 5, white bars). However, 
there was no difference between constitutive cytokine levels (Fig. 5, white bars) and 
those produced following IC stimulation (Fig. 14B, white bars). Due to the pleiotropic 
effects of IL-6, these results cannot be attributed to either a pro- or anti-inflammatory 
phenotype. 
 
Intestinal muscle macrophages from uninfected mice produced significantly lower 
concentrations of the chemokine IP-10 upon LPS stimulation (Fig. 14A, white bars) when 
compared to IC stimulation (Fig. 14B, white bars). Conversely, KC was significantly 
higher following stimulation with LPS than with IC. No difference was seen in MCP-1 
production between stimulation with LPS or IC (Fig. 14, white bars). Production of IP-10 
by intestinal macrophages was significantly higher than that seen in control macrophages 
with both stimulations, while MCP-1 was production was significantly lower (Fig. 14). 
After LPS stimulation, intestinal and control macrophages produced similar 
concentrations of KC; but with IC stimulation, BMMΦ produced significantly more KC 
than muscle macrophages (Fig. 14). When compared to constitutive expression (Fig. 5, 
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white bars), IP-10 production by intestinal macrophages was significantly higher upon 
stimulation with both LPS and IC (Fig. 14, white bars). Macrophages stimulated with 
LPS but not IC produced KC in significantly higher concentrations (Fig 14, white bars) 
compared to day 0 (Fig 5, white bars). MCP-1 levels were not altered in response to 
either stimulation (Fig. 14B and Fig 5, white bars). As expected, these data show that 
intestinal muscle macrophages produce cytokines and chemokines in response to both 
pro- and anti-inflammatory stimulation.  
 
Macrophages cultured from infected mice were also stimulated to investigate the 
effects of Helicobacter on cytokine and chemokine production. Though macrophages 
from infected mice produced large amounts of IL-6, these cells produced significantly 
lower concentrations of IL-6 and TNF-α upon stimulation with LPS than macrophages 
from uninfected mice (Fig. 14A). Macrophages from infected mice also produced 
significantly less IL-6 and TNF-α upon stimulation with IC when compared to those from 
uninfected mice (Fig. 14B). Stimulation by both LPS (Fig. 14A) and IC (Fig. 14B) 
significantly reduced IP-10, MCP-1, and KC production by macrophages from infected 
mice when compared to those from uninfected mice. Therefore, these data demonstrate 
that Helicobacter infection alters the response of intestinal muscle macrophages to both 
LPS- and IC- mediated stimulation. The mechanism by which this occurs is unknown, 
but may involve production of inhibitors of macrophage activation.  
 
Due to the decreased cytokine and chemokine responses of macrophages from 
infected mice, we hypothesized that Helicobacter infection may induce production of 
inhibitors that block stimulation by LPS or IC. Therefore, transcription of several 
negative regulators of macrophage signaling, SIGIRR, ST2 and IRAK-M, were 
investigated. After stimulation, intestinal macrophages expressed low levels of SIGIRR 
(Fig. 12C and 13C), ST2 (<0.19±0.1 units/GAPDH) and IRAK-M (<0.07±0.03 
units/GAPDH). However, macrophages from infected or uninfected mice produced 
similar levels of these genes. Therefore, though the mechanism remains unclear, 
Helicobacter infection alters the phenotype of intestinal muscle macrophages and their 
response to stimuli. 
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Figure 14. Helicobacter infection decreases production of cytokines and chemokines 
by intestinal muscle macrophages in response to stimulation. 
Intestinal muscle macrophages were isolated from uninfected (□) or Helicobacter-
infected (■) mice and cultured in M-CSF for 7 days prior to stimulation with (A) IFN-γ 
and LPS or (B) IL-4 and IC. Supernatants were collected and assayed for IL-6, TNF, IP-
10, MCP-1, and KC production with a Lincoplex kit. Results were analyzed using 
MiraiBio software. BMMΦ cultured in M-CSF and stimulated with IFN and LPS ( ) or 
IL-4 and IC ( ) were used as controls. Each bar represents the average of 3-7 
independent experiments measuring duplicate supernatants, *p<0.05 infected compared 
to uninfected. 
A 
B 
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Helicobacter infection decreases PGE2 production in response to in vitro 
stimulation without altering COX-2 expression 
Rat intestinal muscle macrophages produce PGE2 in response to LPS stimulation 
(65). As a result, arachidonic acid metabolism by macrophages from infected and 
uninfected mice was investigated in response to stimulation. We hypothesized that, 
similar to cytokine production, Helicobacter infection would reduce the production of the 
arachidonic acid metabolites, LTB4 and PGE2, in response to stimulation.  
 
Intestinal muscle macrophages from uninfected mice produced similar amounts of 
LTB4 when stimulated with either LPS or IC (Fig. 15A, white bars). Control 
macrophages also released similar concentrations of LTB4 with both stimulations (Fig. 
15). When compared to constitutive LTB4 production (Fig 6, white bar), LPS or IC 
stimulation did not change the concentration secreted by these macrophages (Fig. 15). 
These data show stimulation does not alter production of LTB4 by intestinal muscle 
macrophages. 
 
Conversely, stimulation did have an effect on PGE2 production. LPS stimulation 
of intestinal muscle macrophages from uninfected mice produced significantly more 
PGE2 than IC stimulation (Fig. 15B, white bars). After LPS stimulation, intestinal 
macrophages secreted significantly less PGE2 than control BMMΦ macrophages. In 
contrast, with IC stimulation, intestinal macrophages and BMMΦ produced similar 
concentrations of PGE2 (Fig. 15). Macrophages produced similar levels of PGE2 
constitutively at day 0 and upon LPS stimulation (Fig. 6 and 15B, white bars), but this 
was significantly higher than that seen at day 7 without stimulation (Fig. 11). 
Macrophages produced significantly less PGE2 after IC stimulation (Fig. 15B, white bars) 
compared to day 0 (Fig. 6, white bar), but these concentrations were similar to day 7 
without stimulation (Fig. 11). These data indicate that LPS induces production of PGE2 
above the constitutive levels seen at day 7 but not above day 0 concentrations. In 
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addition, IC stimulation does not induce intestinal muscle macrophages to produce PGE2 
above constitutive levels observed at day 7. 
 
Investigation of arachidonic acid metabolism by macrophages from infected mice 
showed no difference in LTB4 production upon stimulation with LPS or IC (Fig. 15A). 
There was also no difference in LTB4 between macrophages from infected or uninfected 
mice (Fig 15A). However, macrophages from infected mice produced significantly less 
PGE2 when stimulated with either LPS or IC compared to those from uninfected mice 
(Fig. 15B). Surprisingly, LPS or IC stimulation (Fig. 15B) of macrophages from infected 
mice did not significantly change PGE2 production from that seen after 7 days in culture 
(Fig. 11). This demonstrates that without altering LTB4 production, Helicobacter 
infection decreases PGE2 production by intestinal muscle macrophages after stimulation 
when compared to those from uninfected mice. 
 
Altered PGE2 production again suggests that COX-2 may be altered or inhibited. 
To investigate this phenomenon, we analyzed COX-2 expression by RT-PCR. In response 
to stimulation macrophages from both infected and uninfected mice expressed low levels 
of COX-2 (Fig. 12 and 13). Despite lower PGE2 protein levels in macrophages from 
infected mice following LPS stimulation (Fig. 15B), infection did not change COX-2 
expression in intestinal muscle macrophages (Fig, 12C). COX-2 expression was slightly 
but not significantly lower in macrophages from infected mice after IC stimulation (Fig. 
13C). However, these results did not correlate with the observed decrease in PGE2 
production. Therefore, infection with Helicobacter decreases PGE2 production without 
altering COX-2 expression. 
 
Macrophages found in the intestinal muscle of rats produce NO in response to 
LPS (65). Therefore, we hypothesized that mouse intestinal muscle macrophages would 
generate the pro-inflammatory product NO in response to stimulation with LPS but not 
IC and that Helicobacter infection would alter this response. Though produced by control 
thioglycollate-elicited peritoneal macrophages in response to LPS and IFN-γ, intestinal 
muscle macrophages from uninfected mice did not produce NO after LPS or IC 
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stimulation (data not shown). Similarly, no detectable amounts of NO were produced by 
macrophages from infected mice upon stimulation with either LPS or IC (data not 
shown). These results are the same as those observed with constitutive production 
indicating that mouse intestinal muscle macrophages do not produce NO. This further 
suggests that macrophages in the intestinal muscularis do not have a pro-inflammatory 
phenotype. Taken together with the cytokine and chemokine secretion data, this indicates 
that Helicobacter may be altering production of certain products by macrophages without 
altering the general phenotype of these cells.  
 
Overall, Helicobacter infection alters the response of intestinal muscle 
macrophages to stimulation with either IC or LPS. Helicobacter infection results in 
decreased production of cytokines and chemokines (Fig. 14), as well as PGE2 (Fig. 15B), 
in response to both LPS and IC stimulation.  
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Figure 15. Helicobacter infection alters PGE2 but not LTB4 production by intestinal 
muscle macrophages in response to stimulation. 
Intestinal muscle macrophages were isolated from uninfected (□) or Helicobacter-
infected (■) mice were cultured 7 days with M-CSF, then stimulated with IFN and LPS 
or IL-4 and IC. BMMΦ cultured in M-CSF and stimulated with IFN and LPS ( ) or IL-4 
and IC ( ) were used as controls. Supernatants were collected and assayed by EIA for 
(A) LTB4 or (B) PGE2. Each bar represents the average of 5-7 independent experiments 
measuring duplicate supernatants *p<0.05 infected compared to uninfected. 
B 
A 
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Discussion 
Helicobacter infection alters the phenotype and function of intestinal muscle 
macrophages. Macrophages from infected mice express increased F4/80 and CD11b both 
in vivo (Fig. 2) and after 7 days in culture (Fig. 7). Macrophages from infected mice also 
demonstrate increased phagocytosis (Fig. 10). Though constitutive production is not 
altered (Fig. 5 and 6), macrophages from infected mice exhibit decreased cytokine (Fig. 
14), chemokine (Fig. 14), and PGE2 (Fig. 15) production in response to stimulation with 
both LPS and IC. In addition, Helicobacter alters constitutive gene expression by 
macrophages (Fig. 3) but does not alter gene expression after stimulation (Fig. 12 and 
13). These data show that Helicobacter infection alters the phenotype and function of 
intestinal muscle macrophages as well as their response to stimulation in vitro. 
 
Helicobacter infection alters cytokine and chemokine production in the intestine 
and colon (229, 230). Macrophages may responsible for this change, but the actual source 
is unknown. As a result, understanding the production of secreted factors by resident 
macrophages in response to infection (Fig. 5 and 6) or injury has important implications. 
The removal by depletion or lack of macrophages in the intestine during injury or 
inflammation changes the host response to the challenge (126). Therefore, altering the 
function of intestinal muscle macrophages likely affects the host response to injury or 
inflammation. Helicobacter, by altering macrophages in the intestine, can thereby control 
or modulate the inflammatory response. This may contribute to the persistence of 
Helicobacter infection. However, despite the investigation of several inducible inhibitors 
of LPS signaling (Fig. 12C, 13C, and data not shown), the mechanism by which this 
occurs remains unknown. The course of the infection may also affect macrophages. 
Because Helicobacter infection spreads slowly through a colony, the duration and level 
of infection may lead to some variation in the effects observed. 
 
Despite the assessed purity of these cultures, macrophages isolated from the 
intestinal muscle of both infected and uninfected mice display some heterogeneity since 
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size and staining intensity varies (Fig 7). Due to the limitations of the method used, 
isolation of intestinal muscle macrophages may not exclude all other cell types and the 
culture may not be pure. However, flow cytometry, PCR analysis, and culture with 
FibrOut showed that these cultures contained few to no dendritic cells, T cells, 
endothelial cells, or fibroblasts. Therefore, these cultures are relatively pure indicating 
that the macrophage population itself may be heterogeneous.  
 
The phenotype of intestinal muscle macrophages and their immunologic function 
has not been well defined. The phenotype observed in this study does not correlate with 
any of the known macrophage phenotypes (69, 75). Intestinal muscle macrophages from 
uninfected mice express more of the genes associated with an anti-inflammatory (M2) 
phenotype (Fig. 3 and 13) than a pro-inflammatory (M1) phenotype (Fig. 3 and 12). 
Macrophages from Helicobacter-infected mice express genes associated with both M1 
and M2 phenotypes. The lack of correlation between intestinal muscle macrophages and 
any single macrophage phenotype may be due to the fact that these are tissue 
macrophages. In addition the macrophages used to determine M1 and multiple M2 
phenotypes are induced in vitro from bone marrow and not derived directly from the 
mouse (58, 69, 75). The macrophages found in vivo are likely to be similar, but may not 
display exactly the same characteristics as BMMΦ artificially induced to become M1 or 
M2 macrophages. Although the intermediate phenotype found in the intestinal muscle in 
response to Helicobacter infection would likely be classified as an M2, it suggests that 
this model may not be sufficient to describe the observed phenotypes of tissue 
macrophages ex vivo. In addition, this model likely does not apply to all macrophages 
found in vivo since the phenotypes and functions of tissue macrophages varies depending 
on the location within the body (reviewed in (45)).  
 
Previous studies showed that the intestine contains a network of phagocytic 
F4/80+ macrophages (36, 37, 122, 243). Most studies of intestinal muscle macrophages 
use Fitc-dextran (36, 37, 122, 127, 128, 243), labeled E. coli particles (120, 244), or small 
fluorescent microspheres (117, 118, 123). These are small particles that can be taken up 
by endocytosis rather than being phagocytosed. A novel aspect of this work is the use of 
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large zymosan particles which can only be phagocytosed (Fig. 9). Phagocytosis of large 
necrotic cell debris by macrophages induces an anti-inflammatory phenotype (129). 
Therefore the ability of intestinal muscle macrophages to ingest large particles may prove 
more effective in determining their role in intestinal inflammation, homeostasis, and 
repair. In response to Helicobacter infection, macrophages in the intestinal muscle were 
three times more phagocytic for zymosan particles (Fig. 9). Though Helicobacter inhibits 
stimulation of cytokine and chemokine production, the mechanism of inhibition of LPS 
and IC signaling does not affect the pathways governing phagocytosis.  
 
The most commonly used technique for cellular identification is surface marker 
expression. Macrophages in this study were identified by flow cytometry and IHC using a 
variety of surface markers some of which were altered in response to infection. 
Helicobacter increased the expression of F4/80 or CD11b on macrophages in vivo (Fig. 
2) or in vitro (Fig. 7) by IHC. The flow cytometry in this and other studies shows isolated 
intestinal macrophages express relatively low levels of characteristic macrophage 
markers such as F4/80 and CD14 (Fig. 8 and (119)). This may be due to the use of 
enzymes during isolation that may interfere with the staining process. However, our 
preliminary data using a macrophage cell line indicates that collagenase treatment does 
not decrease surface marker expression as analyzed by flow cytometry (data not shown). 
Another possibility is that the adherent nature of intestinal macrophages may cause 
difficulty during flow cytometric analysis. To avoid these issues, we also analyzed 
intestinal muscle macrophages by IHC (Fig. 7) which has been shown previously to 
identify macrophages similar to those we observed in the intestinal muscularis layers (36, 
37, 243). As it provided better representative staining, we believe that IHC may be more 
accurate in determining surface marker expression for intestinal muscle macrophages.  
 
Cytokine and chemokine production by intestinal muscle macrophages in 
response to stimulation has been largely undetermined in previous work. Therefore, we 
analyzed cytokine and chemokine production by intestinal muscle macrophages both 
constitutively (Fig. 5) and in response to LPS and IC stimulation (Fig. 14). Other studies 
showed that human intestinal macrophages produce IL-8 but not IL-6 or TNF in response 
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to LPS (117, 119). However, we observed production of KC, IL-6, and TNF 
constitutively (Fig. 5) and after stimulation with either LPS or IC (Fig. 14). One 
interesting observation was the constitutively high levels of IL-6 observed in 
macrophages in the intestinal muscle (Fig. 4 and 5). Though IL-6 is typically thought of 
as a pro-inflammatory cytokine, muscle contraction alone contributes to IL-6 production 
(137, 139). Therefore, based on the tissue location of these cells, IL-6 cannot be viewed 
solely as inflammatory. However our co-localization studies show that macrophages 
produce the majority of IL-6 in whole mounts of intestinal muscle (Fig. 4). This study 
also expands the range of chemokines produced by intestinal macrophages, both with and 
without stimulation. Previously studies showed that human monocytes cultured to have 
anti-inflammatory phenotype produce chemokines such as IL-8, IP-10, and MCP-1 in 
response to LPS (69). We obtained similar results upon stimulation of muscularis 
macrophages (Fig. 5 and 14). This further suggests that intestinal muscle macrophages 
produce a wide range of factors but do not fall into a single classification. 
 
The production of cytokines and chemokines by intestinal macrophages in 
response to chronic Helicobacter infection has not been investigated in previous studies. 
Helicobacter infection increases MIP-1α and IP-10 mRNA in cecal tissue (229), while 
peripheral blood monocytes and macrophage cell lines produce IL-6, IL-8, and NO in 
response to Helicobacter stimulation in vitro (230, 238, 239). However, we show that 
Helicobacter infection results in decreased cytokine and chemokine production by 
intestinal muscle macrophages in response to stimulation with either LPS or IC in vitro 
(Fig. 14). This suggests that in vivo infection likely results in a different response than in 
vitro stimulation. In addition, these data show macrophages from infected mice have 
altered responses to in vitro stimulation.  
 
Arachidonic acid metabolites are critical to inflammation and to the resolution of 
the response. Peripheral blood monocytes and other tissue macrophages secrete the 
arachidonic acid products, LTB4 and PGE2 in response to in vitro stimulation with LPS 
and IC (192, 245). Our data extend these findings to show that intestinal muscle 
macrophages constitutively produce LTB4 (Fig. 6). Neither Helicobacter infection (Fig. 
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6) nor in vitro stimulation (Fig. 15) alters secretion of LTB4. Moreover, we showed that 
macrophages produced PGE2 constitutively (Fig. 6) and in response to LPS but not IC 
stimulation (Fig. 15). This correlates with previous studies showing that PGE2 and COX-
2 production co-localizes with macrophage markers in the intestinal muscle after LPS 
stimulation (65). Chronic, in vivo infection with Helicobacter does not alter constitutive 
production of PGE2. However, macrophages cultured from Helicobacter-infected mice 
secrete significantly reduced concentrations of PGE2 (Fig. 11). Helicobacter infection 
also decreases PGE2 in response to in vitro stimulation (Fig. 15). This suggests that in 
vitro stimulation is not necessarily similar to infection when determining production of 
arachidonic acid metabolites. 
 
Originally considered to be a commensal bacterium, researchers did not consider 
Helicobacter infection to alter experimental studies performed on infected mice. This 
study and others suggest that may not be the case. Due to the large number of infected 
mice, alteration of the inflammatory response by Helicobacter has a potentially 
significant effect on the results of present and future animal studies as well as the analysis 
of previous work. 
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